US20140303125A1 - Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency - Google Patents
Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency Download PDFInfo
- Publication number
- US20140303125A1 US20140303125A1 US14/310,690 US201414310690A US2014303125A1 US 20140303125 A1 US20140303125 A1 US 20140303125A1 US 201414310690 A US201414310690 A US 201414310690A US 2014303125 A1 US2014303125 A1 US 2014303125A1
- Authority
- US
- United States
- Prior art keywords
- dimethylamino
- tetrahydro
- diazafluorene
- pentamethylene
- phenylpentamethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CRRFNIPBMBTDTD-UHFFFAOYSA-N CC1CC2=C(NC3=C2C=CC=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)N1 Chemical compound CC1CC2=C(NC3=C2C=CC=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)N1 CRRFNIPBMBTDTD-UHFFFAOYSA-N 0.000 description 4
- CSMVOZKEWSOFER-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 CSMVOZKEWSOFER-UHFFFAOYSA-N 0.000 description 3
- JCROKVWSGUVMAM-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)SCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)SCCC1=C2NC2=C1C=CC=C2 JCROKVWSGUVMAM-UHFFFAOYSA-N 0.000 description 3
- VXQDXHKOIBIEGT-UHFFFAOYSA-N CC1=CC=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)C=C1 Chemical compound CC1=CC=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)C=C1 VXQDXHKOIBIEGT-UHFFFAOYSA-N 0.000 description 2
- ANUHWKMJZIWIFE-UHFFFAOYSA-N CC1CC2=C(NC3=C2C=CC=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 Chemical compound CC1CC2=C(NC3=C2C=CC=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 ANUHWKMJZIWIFE-UHFFFAOYSA-N 0.000 description 2
- SYUVIKIQFLDTBX-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c3ccccc3[nH]1)N2C(CCc1ccccc1)=O)c1ccccc1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c3ccccc3[nH]1)N2C(CCc1ccccc1)=O)c1ccccc1 SYUVIKIQFLDTBX-UHFFFAOYSA-N 0.000 description 2
- PQTKJTOQDIYLOA-UHFFFAOYSA-N CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(c(Cl)ccc1)c1Cl)=O Chemical compound CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(c(Cl)ccc1)c1Cl)=O PQTKJTOQDIYLOA-UHFFFAOYSA-N 0.000 description 2
- KOSHRNJMVKAEQN-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=CC=C2)C2=C(C=CC=C2)C1 KOSHRNJMVKAEQN-UHFFFAOYSA-N 0.000 description 2
- LHYHJAMYFCDXTL-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=C(F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=C(F)C=C2)C2=C(C=CC=C2)C1 LHYHJAMYFCDXTL-UHFFFAOYSA-N 0.000 description 2
- YIEUAZDBIQNLDJ-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CC=C2)C2=C(C=CC=C2)C1 YIEUAZDBIQNLDJ-UHFFFAOYSA-N 0.000 description 2
- NEOYYOIAYKLHGL-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CCC2=CC=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CCC2=CC=CC=C2)C2=C(C=CC=C2)C1 NEOYYOIAYKLHGL-UHFFFAOYSA-N 0.000 description 2
- BGIGFDPKVDAIBC-UHFFFAOYSA-N CN(C)C1(C2=CC=CS2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CS2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 BGIGFDPKVDAIBC-UHFFFAOYSA-N 0.000 description 2
- DAYAPIUIJSWIHD-UHFFFAOYSA-N CN(C)C1(C2=CSC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 Chemical compound CN(C)C1(C2=CSC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 DAYAPIUIJSWIHD-UHFFFAOYSA-N 0.000 description 2
- JCNJOWAWGBIQDS-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(Cl)C=CC=C2Cl)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(Cl)C=CC=C2Cl)C2=C(C=CC=C2)C1 JCNJOWAWGBIQDS-UHFFFAOYSA-N 0.000 description 2
- RLYCCRVHSUAVER-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2F)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2F)C2=C(C=CC=C2)C1 RLYCCRVHSUAVER-UHFFFAOYSA-N 0.000 description 2
- TXZMBWWDCWSSOW-UHFFFAOYSA-N CN1C2=C(C=CC=C2)C2=C1C1(CCC(C3=CC=CC=C3)(N(C)C)CC1)OCC2.Cl Chemical compound CN1C2=C(C=CC=C2)C2=C1C1(CCC(C3=CC=CC=C3)(N(C)C)CC1)OCC2.Cl TXZMBWWDCWSSOW-UHFFFAOYSA-N 0.000 description 2
- MHPDZNVIBXTODU-UHFFFAOYSA-N COC(=O)CCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound COC(=O)CCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 MHPDZNVIBXTODU-UHFFFAOYSA-N 0.000 description 2
- VNBJYDDFIRRYLO-UHFFFAOYSA-N COC1=CC=CC(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)=C1 Chemical compound COC1=CC=CC(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)=C1 VNBJYDDFIRRYLO-UHFFFAOYSA-N 0.000 description 2
- NKOQRTYLFHGXEJ-UHFFFAOYSA-N C1=CC=C(C2(N3CCCC3)CCC3(CC2)OCCC2=C3NC3=C2C=CC=C3)C=C1 Chemical compound C1=CC=C(C2(N3CCCC3)CCC3(CC2)OCCC2=C3NC3=C2C=CC=C3)C=C1 NKOQRTYLFHGXEJ-UHFFFAOYSA-N 0.000 description 1
- AQWAZYFWEZLRMD-QGMBQPNBSA-N C=C/C=C(\C=C)C1(N(C)C)CCC2(CC1)OC(C)CC1=C2NC2=C1C=C([N+](=O)[O-])C=C2 Chemical compound C=C/C=C(\C=C)C1(N(C)C)CCC2(CC1)OC(C)CC1=C2NC2=C1C=C([N+](=O)[O-])C=C2 AQWAZYFWEZLRMD-QGMBQPNBSA-N 0.000 description 1
- QBBRQQIXCSEDHE-UHFFFAOYSA-N CC(=O)N1CCC2=C(NC3=C2C=CC(F)=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound CC(=O)N1CCC2=C(NC3=C2C=CC(F)=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 QBBRQQIXCSEDHE-UHFFFAOYSA-N 0.000 description 1
- SFPYLUBLTMQIOV-UHFFFAOYSA-N CC(=O)N1CCC2=C(NC3=C2C=CC=C3)C12CCC(C1=CC=C(F)C=C1)(N(C)C)CC2 Chemical compound CC(=O)N1CCC2=C(NC3=C2C=CC=C3)C12CCC(C1=CC=C(F)C=C1)(N(C)C)CC2 SFPYLUBLTMQIOV-UHFFFAOYSA-N 0.000 description 1
- OZMIXURVHNPRPT-UHFFFAOYSA-N CC(=O)N1CCC2=C(NC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound CC(=O)N1CCC2=C(NC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 OZMIXURVHNPRPT-UHFFFAOYSA-N 0.000 description 1
- SOOIUTLKHCXCCR-UHFFFAOYSA-N CC(=O)N1CCC2=C(OC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound CC(=O)N1CCC2=C(OC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 SOOIUTLKHCXCCR-UHFFFAOYSA-N 0.000 description 1
- JLBAYNUDGQZGKY-UHFFFAOYSA-N CC(C)CC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound CC(C)CC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 JLBAYNUDGQZGKY-UHFFFAOYSA-N 0.000 description 1
- XFEBOUWTGBDRMO-UHFFFAOYSA-N CC1=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)C=CC=C1 Chemical compound CC1=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)C=CC=C1 XFEBOUWTGBDRMO-UHFFFAOYSA-N 0.000 description 1
- QNSIMLFROVUWMQ-UHFFFAOYSA-N CC1=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC=CC=C2)(N(C)C)CC3)C=CC=C1 Chemical compound CC1=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC=CC=C2)(N(C)C)CC3)C=CC=C1 QNSIMLFROVUWMQ-UHFFFAOYSA-N 0.000 description 1
- UZAPAZJPKCHCMU-UHFFFAOYSA-N CC1=C(F)C(F)=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC=CC=C2)(N(C)C)CC3)C(F)=C1C Chemical compound CC1=C(F)C(F)=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC=CC=C2)(N(C)C)CC3)C(F)=C1C UZAPAZJPKCHCMU-UHFFFAOYSA-N 0.000 description 1
- OCMFMLCSFZLKDQ-UHFFFAOYSA-N CC1=CC(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)=CC=C1 Chemical compound CC1=CC(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)=CC=C1 OCMFMLCSFZLKDQ-UHFFFAOYSA-N 0.000 description 1
- OZDIMMWNIHJMQL-UHFFFAOYSA-N CC1=CC(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(CC2=CC=CC=C2)(N(C)C)CC3)=CC=C1 Chemical compound CC1=CC(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(CC2=CC=CC=C2)(N(C)C)CC3)=CC=C1 OZDIMMWNIHJMQL-UHFFFAOYSA-N 0.000 description 1
- FJCNUXXAHZVGIR-UHFFFAOYSA-N CC1=CC2=C(C=C1)NC1=C2CC(C)OC12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound CC1=CC2=C(C=C1)NC1=C2CC(C)OC12CCC(C1=CC=CC=C1)(N(C)C)CC2 FJCNUXXAHZVGIR-UHFFFAOYSA-N 0.000 description 1
- BYACUNBCZFSQIX-UHFFFAOYSA-N CC1=CC2=C(C=C1)NC1=C2CCNC12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound CC1=CC2=C(C=C1)NC1=C2CCNC12CCC(C1=CC=CC=C1)(N(C)C)CC2 BYACUNBCZFSQIX-UHFFFAOYSA-N 0.000 description 1
- UUVKKZIRRBVUFP-UHFFFAOYSA-N CC1=CC2=C(C=C1)NC1=C2CCOC12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound CC1=CC2=C(C=C1)NC1=C2CCOC12CCC(C1=CC=CC=C1)(N(C)C)CC2 UUVKKZIRRBVUFP-UHFFFAOYSA-N 0.000 description 1
- KRVKAENJGMNJAT-UHFFFAOYSA-N CC1CC2=C(N(C)C3=C2C=CC=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 Chemical compound CC1CC2=C(N(C)C3=C2C=CC=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 KRVKAENJGMNJAT-UHFFFAOYSA-N 0.000 description 1
- MYBTXSWAAUNNSM-UHFFFAOYSA-N CC1CC2=C(NC3=C2C=C(Br)C=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 Chemical compound CC1CC2=C(NC3=C2C=C(Br)C=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 MYBTXSWAAUNNSM-UHFFFAOYSA-N 0.000 description 1
- WMKUNXSMIUOWCQ-UHFFFAOYSA-N CC1CC2=C(NC3=C2C=C(Cl)C=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 Chemical compound CC1CC2=C(NC3=C2C=C(Cl)C=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 WMKUNXSMIUOWCQ-UHFFFAOYSA-N 0.000 description 1
- PFZLXGIYSYVVJF-UHFFFAOYSA-N CC1CC2=C(NC3=C2C=C(F)C=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 Chemical compound CC1CC2=C(NC3=C2C=C(F)C=C3)C2(CCC(C3=CC=CC=C3)(N(C)C)CC2)O1 PFZLXGIYSYVVJF-UHFFFAOYSA-N 0.000 description 1
- KELBQPOAWCWCOK-UHFFFAOYSA-N CCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2 Chemical compound CCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2 KELBQPOAWCWCOK-UHFFFAOYSA-N 0.000 description 1
- RRZMFBDGNWBMKN-UHFFFAOYSA-N CCCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2 Chemical compound CCCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2 RRZMFBDGNWBMKN-UHFFFAOYSA-N 0.000 description 1
- ZVHZGCSNOZVFMG-UHFFFAOYSA-N CCCCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2 Chemical compound CCCCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2 ZVHZGCSNOZVFMG-UHFFFAOYSA-N 0.000 description 1
- AWXWVMXUUSLDHW-UHFFFAOYSA-N CCCCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(CC1=CC=CC=C1)(N(C)C)CC2 Chemical compound CCCCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(CC1=CC=CC=C1)(N(C)C)CC2 AWXWVMXUUSLDHW-UHFFFAOYSA-N 0.000 description 1
- KVTBIQHRYVWXMJ-UHFFFAOYSA-N CCCCC(CC)C(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound CCCCC(CC)C(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC=CC=C1)(N(C)C)CC2 KVTBIQHRYVWXMJ-UHFFFAOYSA-N 0.000 description 1
- FKXIGWGBIPYMPU-UHFFFAOYSA-N CCCCC(N(CC1)C(CC2)(CCC2(c2cc(F)ccc2)N(C)C)c2c1c(cccc1)c1[nH]2)=O Chemical compound CCCCC(N(CC1)C(CC2)(CCC2(c2cc(F)ccc2)N(C)C)c2c1c(cccc1)c1[nH]2)=O FKXIGWGBIPYMPU-UHFFFAOYSA-N 0.000 description 1
- ZVCOHSZFJRDVNY-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(CCC(OC)=O)=O)c1ccccc1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(CCC(OC)=O)=O)c1ccccc1 ZVCOHSZFJRDVNY-UHFFFAOYSA-N 0.000 description 1
- UBKQZIJJHRGSEW-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(c(C(F)(F)F)ccc1)c1F)=O)c1cc(F)ccc1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(c(C(F)(F)F)ccc1)c1F)=O)c1cc(F)ccc1 UBKQZIJJHRGSEW-UHFFFAOYSA-N 0.000 description 1
- KZCQMUIUUDVPON-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(cc(C(F)(F)F)cc1)c1F)=O)c1ccccc1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(cc(C(F)(F)F)cc1)c1F)=O)c1ccccc1 KZCQMUIUUDVPON-UHFFFAOYSA-N 0.000 description 1
- JTCDHKYINFEWHQ-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(cc1)cc(Cl)c1Cl)=O)c1cc(F)ccc1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(cc1)cc(Cl)c1Cl)=O)c1cc(F)ccc1 JTCDHKYINFEWHQ-UHFFFAOYSA-N 0.000 description 1
- MXSWLPPYJLARDI-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(cc1C(F)(F)F)ccc1F)=O)c1cccc(F)c1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(cc1C(F)(F)F)ccc1F)=O)c1cccc(F)c1 MXSWLPPYJLARDI-UHFFFAOYSA-N 0.000 description 1
- XBUKQAVITLWMEJ-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(cc1F)ccc1F)=O)c1cccc(F)c1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(cc1F)ccc1F)=O)c1cccc(F)c1 XBUKQAVITLWMEJ-UHFFFAOYSA-N 0.000 description 1
- BNBIMEVEATVUSJ-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(ccc(C(F)(F)F)c1)c1F)=O)c1ccccc1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c(ccc(C(F)(F)F)c1)c1F)=O)c1ccccc1 BNBIMEVEATVUSJ-UHFFFAOYSA-N 0.000 description 1
- NNCKYJOVKICMOV-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c1ccccc1)=O)c1cccc(F)c1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c1ccccc1)=O)c1cccc(F)c1 NNCKYJOVKICMOV-UHFFFAOYSA-N 0.000 description 1
- LAUPAFXHKGKXRL-UHFFFAOYSA-N CN(C)C(CC1)(CCC1(c1c(CC2)c3ccccc3[nH]1)N2C(c(cc(C(F)(F)F)cc1)c1F)=O)c1cccc(F)c1 Chemical compound CN(C)C(CC1)(CCC1(c1c(CC2)c3ccccc3[nH]1)N2C(c(cc(C(F)(F)F)cc1)c1F)=O)c1cccc(F)c1 LAUPAFXHKGKXRL-UHFFFAOYSA-N 0.000 description 1
- QZFVXRMCGZIPEW-UHFFFAOYSA-N CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(CCC(OC)=O)=O Chemical compound CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(CCC(OC)=O)=O QZFVXRMCGZIPEW-UHFFFAOYSA-N 0.000 description 1
- BDLXUWITGYPVFT-UHFFFAOYSA-N CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c1ccc(C(F)(F)F)cc1)=O Chemical compound CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c1ccc(C(F)(F)F)cc1)=O BDLXUWITGYPVFT-UHFFFAOYSA-N 0.000 description 1
- QFOQRRKFQGWSGN-UHFFFAOYSA-N CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c1ccccc1[N+]([O-])=O)=O Chemical compound CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c(cccc3)c3[nH]1)N2C(c1ccccc1[N+]([O-])=O)=O QFOQRRKFQGWSGN-UHFFFAOYSA-N 0.000 description 1
- WCKZFBYNQQIDPO-UHFFFAOYSA-N CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c3ccccc3[nH]1)N2C(c(cc(c(F)c1F)F)c1F)=O Chemical compound CN(C)C(Cc1ccccc1)(CC1)CCC1(c1c(CC2)c3ccccc3[nH]1)N2C(c(cc(c(F)c1F)F)c1F)=O WCKZFBYNQQIDPO-UHFFFAOYSA-N 0.000 description 1
- ZHUVNJVATCSLPY-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(Br)C=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(Br)C=CC=C2)C2=C(C=CC=C2)C1 ZHUVNJVATCSLPY-UHFFFAOYSA-N 0.000 description 1
- LEPXTQDHOOUBQL-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(Cl)C=C(Cl)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(Cl)C=C(Cl)C=C2)C2=C(C=CC=C2)C1 LEPXTQDHOOUBQL-UHFFFAOYSA-N 0.000 description 1
- QTGOIVKBCULCGW-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2)C2=C(C=CC=C2)C1 QTGOIVKBCULCGW-UHFFFAOYSA-N 0.000 description 1
- OZDIZEOHLQGIAE-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=CC=C2)C2=C(C=CC=C2)C1 OZDIZEOHLQGIAE-UHFFFAOYSA-N 0.000 description 1
- YCLHTBKEFPYJPN-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=C(C(F)(F)F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=C(C(F)(F)F)C=C2)C2=C(C=CC=C2)C1 YCLHTBKEFPYJPN-UHFFFAOYSA-N 0.000 description 1
- JRGYXSHSLMWXEH-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=C(F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=C(F)C=C2)C2=C(C=CC=C2)C1 JRGYXSHSLMWXEH-UHFFFAOYSA-N 0.000 description 1
- OUJSLQVLRQYEMX-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 OUJSLQVLRQYEMX-UHFFFAOYSA-N 0.000 description 1
- DVZVQVATBNASEE-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2C(F)(F)F)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2C(F)(F)F)C2=C(C=CC=C2)C1 DVZVQVATBNASEE-UHFFFAOYSA-N 0.000 description 1
- UMZJSHMMKPSBTC-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2F)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2F)C2=C(C=CC=C2)C1 UMZJSHMMKPSBTC-UHFFFAOYSA-N 0.000 description 1
- DQBRIQURJIFBAQ-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(C(F)(F)F)=C(F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(C(F)(F)F)=C(F)C=C2)C2=C(C=CC=C2)C1 DQBRIQURJIFBAQ-UHFFFAOYSA-N 0.000 description 1
- BUIVXHYMSHXHAA-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=C(Cl)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=C(Cl)C=C2)C2=C(C=CC=C2)C1 BUIVXHYMSHXHAA-UHFFFAOYSA-N 0.000 description 1
- FDQUSCQHIVDPJJ-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=CC(Cl)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=CC(Cl)=C2)C2=C(C=CC=C2)C1 FDQUSCQHIVDPJJ-UHFFFAOYSA-N 0.000 description 1
- UJAVRQCASMUAQP-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 UJAVRQCASMUAQP-UHFFFAOYSA-N 0.000 description 1
- IDUSEBPYRZOSMB-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(F)=C2)C2=C(C=CC=C2)C1 IDUSEBPYRZOSMB-UHFFFAOYSA-N 0.000 description 1
- BRTMJAOYVBKPSH-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(C(C)(C)C)C=C2)C2=C(C=CC=C2)C1.S Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(C(C)(C)C)C=C2)C2=C(C=CC=C2)C1.S BRTMJAOYVBKPSH-UHFFFAOYSA-N 0.000 description 1
- IYCDDMXPUNEOOT-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(F)C=C2)C2=C(C=CC=C2)C1 IYCDDMXPUNEOOT-UHFFFAOYSA-N 0.000 description 1
- WATROQFWIIXYOO-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C([N+](=O)[O-])C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C([N+](=O)[O-])C=C2)C2=C(C=CC=C2)C1 WATROQFWIIXYOO-UHFFFAOYSA-N 0.000 description 1
- HROFVUAJKSXCPY-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CC=C2)C2=C(C=CC=C2)C1 HROFVUAJKSXCPY-UHFFFAOYSA-N 0.000 description 1
- FGAULNWIMXNKJE-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CO2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CO2)C2=C(C=CC=C2)C1 FGAULNWIMXNKJE-UHFFFAOYSA-N 0.000 description 1
- TWDHBBNVCOXDGH-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCCCC2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCCCC2)C2=C(C=CC=C2)C1 TWDHBBNVCOXDGH-UHFFFAOYSA-N 0.000 description 1
- DLTBMCIJBRIFIV-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC(C)(C)C)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC(C)(C)C)C2=C(C=CC=C2)C1 DLTBMCIJBRIFIV-UHFFFAOYSA-N 0.000 description 1
- FLDDAZYOJLYRMJ-UHFFFAOYSA-N CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CS2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC(F)=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CS2)C2=C(C=CC=C2)C1 FLDDAZYOJLYRMJ-UHFFFAOYSA-N 0.000 description 1
- NCQSIDKZYNISTD-UHFFFAOYSA-N CN(C)C1(C2=CC=C(F)C=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=C(F)C=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC=C2 NCQSIDKZYNISTD-UHFFFAOYSA-N 0.000 description 1
- MKCHPQVQUVWXTG-UHFFFAOYSA-N CN(C)C1(C2=CC=C(F)C=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=C(F)C=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 MKCHPQVQUVWXTG-UHFFFAOYSA-N 0.000 description 1
- MBAJGWVSOJXJBY-UHFFFAOYSA-N CN(C)C1(C2=CC=CC(F)=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC(F)=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC=C2 MBAJGWVSOJXJBY-UHFFFAOYSA-N 0.000 description 1
- BPLIYLNYFXWJRQ-UHFFFAOYSA-N CN(C)C1(C2=CC=CC(F)=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC(F)=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 BPLIYLNYFXWJRQ-UHFFFAOYSA-N 0.000 description 1
- RJWBNKNOJHAUPJ-UHFFFAOYSA-N CN(C)C1(C2=CC=CC(O)=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC(O)=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 RJWBNKNOJHAUPJ-UHFFFAOYSA-N 0.000 description 1
- UXDJJCDMFIHZJV-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=CC=C2)C2=C(C=CC=C2)C1 UXDJJCDMFIHZJV-UHFFFAOYSA-N 0.000 description 1
- CUFXWSGTSOSSDU-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 CUFXWSGTSOSSDU-UHFFFAOYSA-N 0.000 description 1
- UPGGQAHGRBQWGX-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC(F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC(F)=C2)C2=C(C=CC=C2)C1 UPGGQAHGRBQWGX-UHFFFAOYSA-N 0.000 description 1
- OXHVXSHXFLSPGH-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2)C2=C(C=CC=C2)C1 OXHVXSHXFLSPGH-UHFFFAOYSA-N 0.000 description 1
- PQHCBSTUVNVKGI-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2F)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2F)C2=C(C=CC=C2)C1 PQHCBSTUVNVKGI-UHFFFAOYSA-N 0.000 description 1
- XXQBDVYBVSNDDV-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(C(F)(F)F)=C(F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(C(F)(F)F)=C(F)C=C2)C2=C(C=CC=C2)C1 XXQBDVYBVSNDDV-UHFFFAOYSA-N 0.000 description 1
- BUANOYAKSCVDPL-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=C(Cl)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=C(Cl)C=C2)C2=C(C=CC=C2)C1 BUANOYAKSCVDPL-UHFFFAOYSA-N 0.000 description 1
- QKAZPWZWQCQXCN-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=CC(Cl)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(Cl)=CC(Cl)=C2)C2=C(C=CC=C2)C1 QKAZPWZWQCQXCN-UHFFFAOYSA-N 0.000 description 1
- GKDUHIGDZZOEBZ-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=C(F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=C(F)C=C2)C2=C(C=CC=C2)C1 GKDUHIGDZZOEBZ-UHFFFAOYSA-N 0.000 description 1
- SJSMBQKRAQBPHK-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 SJSMBQKRAQBPHK-UHFFFAOYSA-N 0.000 description 1
- PZXAMDYHUZYEAM-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(F)=C2)C2=C(C=CC=C2)C1 PZXAMDYHUZYEAM-UHFFFAOYSA-N 0.000 description 1
- ASNMSNQFCXCCON-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC=C2)C2=C(C=CC=C2)C1 ASNMSNQFCXCCON-UHFFFAOYSA-N 0.000 description 1
- MPXWNAJVIBFBGL-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC([N+](=O)[O-])=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC([N+](=O)[O-])=CC=C2)C2=C(C=CC=C2)C1 MPXWNAJVIBFBGL-UHFFFAOYSA-N 0.000 description 1
- VNDDLSPVUJAMOM-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(C(F)(F)F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(C(F)(F)F)C=C2)C2=C(C=CC=C2)C1 VNDDLSPVUJAMOM-UHFFFAOYSA-N 0.000 description 1
- XDPOAJHZHNWZER-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1 XDPOAJHZHNWZER-UHFFFAOYSA-N 0.000 description 1
- RPPJETOGQYLEKR-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CO2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CO2)C2=C(C=CC=C2)C1 RPPJETOGQYLEKR-UHFFFAOYSA-N 0.000 description 1
- CMRDZZONLWMAMI-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CS2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CS2)C2=C(C=CC=C2)C1 CMRDZZONLWMAMI-UHFFFAOYSA-N 0.000 description 1
- HBNCWNPBKLURFQ-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCC2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCC2)C2=C(C=CC=C2)C1 HBNCWNPBKLURFQ-UHFFFAOYSA-N 0.000 description 1
- PXFGIBPPRCGDKK-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCCC2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCCC2)C2=C(C=CC=C2)C1 PXFGIBPPRCGDKK-UHFFFAOYSA-N 0.000 description 1
- KPSJHQTXWLMRCN-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCCCC2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCCCC2)C2=C(C=CC=C2)C1 KPSJHQTXWLMRCN-UHFFFAOYSA-N 0.000 description 1
- LJKCZZUJWCEFAY-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC(C)(C)C)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC(C)(C)C)C2=C(C=CC=C2)C1 LJKCZZUJWCEFAY-UHFFFAOYSA-N 0.000 description 1
- HXNHFZTVKZZCCP-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CS2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CS2)C2=C(C=CC=C2)C1 HXNHFZTVKZZCCP-UHFFFAOYSA-N 0.000 description 1
- AEHYQICOEZHREH-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CCC2CCCC2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CCC2CCCC2)C2=C(C=CC=C2)C1 AEHYQICOEZHREH-UHFFFAOYSA-N 0.000 description 1
- QCGAYDNPFDIKHQ-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CC[SH]2O)C2=C(C=CC=C2)N1 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)C1=C(CC[SH]2O)C2=C(C=CC=C2)N1 QCGAYDNPFDIKHQ-UHFFFAOYSA-N 0.000 description 1
- DKFASWFMDDJHAC-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NC(CO)CC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NC(CO)CC1=C2NC2=C1C=CC=C2 DKFASWFMDDJHAC-UHFFFAOYSA-N 0.000 description 1
- ITKKCZHFVQZDNH-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NC(COC=O)CC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NC(COC=O)CC1=C2NC2=C1C=CC=C2 ITKKCZHFVQZDNH-UHFFFAOYSA-N 0.000 description 1
- JBRPRZXCKRICQC-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NCCC1=C2NC2=C1C=C(F)C=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NCCC1=C2NC2=C1C=C(F)C=C2 JBRPRZXCKRICQC-UHFFFAOYSA-N 0.000 description 1
- HXDWGMGPWBSVQP-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC(F)=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC(F)=C2 HXDWGMGPWBSVQP-UHFFFAOYSA-N 0.000 description 1
- FPSHFESBMNTMNM-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC=C2 FPSHFESBMNTMNM-UHFFFAOYSA-N 0.000 description 1
- NJFJPSNQMBTDSQ-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NCCC1=C2OC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)NCCC1=C2OC2=C1C=CC=C2 NJFJPSNQMBTDSQ-UHFFFAOYSA-N 0.000 description 1
- LZWKURSKJSJXBN-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OC1CCCCC1C1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OC1CCCCC1C1=C2NC2=C1C=CC=C2 LZWKURSKJSJXBN-UHFFFAOYSA-N 0.000 description 1
- LMNLKKQGOKFROX-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2CC2=C1C=C(C1=CN(CC3=CC=CC=C3)N=C1)C=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2CC2=C1C=C(C1=CN(CC3=CC=CC=C3)N=C1)C=C2 LMNLKKQGOKFROX-UHFFFAOYSA-N 0.000 description 1
- HLAVHUNUFQQSRT-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C(Cl)=CC(Cl)=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C(Cl)=CC(Cl)=C2 HLAVHUNUFQQSRT-UHFFFAOYSA-N 0.000 description 1
- FNTBKHJJPRNLMX-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(Br)C=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(Br)C=C2 FNTBKHJJPRNLMX-UHFFFAOYSA-N 0.000 description 1
- VDJIXTIKWWDTNL-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(C1=CC=CN=C1)C=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(C1=CC=CN=C1)C=C2 VDJIXTIKWWDTNL-UHFFFAOYSA-N 0.000 description 1
- CNGSWXFGRMDWOA-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(C1=NC=CS1)C=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(C1=NC=CS1)C=C2 CNGSWXFGRMDWOA-UHFFFAOYSA-N 0.000 description 1
- KFKGRKGKOJKTPF-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(O)C=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(O)C=C2 KFKGRKGKOJKTPF-UHFFFAOYSA-N 0.000 description 1
- VPEGVUKAEWECTI-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC(Cl)=C2Cl Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC(Cl)=C2Cl VPEGVUKAEWECTI-UHFFFAOYSA-N 0.000 description 1
- PICPCIFZWHBKPD-UHFFFAOYSA-N CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 PICPCIFZWHBKPD-UHFFFAOYSA-N 0.000 description 1
- RFLKMKOKOHCGJR-UHFFFAOYSA-N CN(C)C1(C2=CC=CS2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 Chemical compound CN(C)C1(C2=CC=CS2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 RFLKMKOKOHCGJR-UHFFFAOYSA-N 0.000 description 1
- XEVNGYOYQJXDDK-UHFFFAOYSA-N CN(C)C1(C2=CSC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(C2=CSC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 XEVNGYOYQJXDDK-UHFFFAOYSA-N 0.000 description 1
- XGZFPMKIFPFGTB-UHFFFAOYSA-N CN(C)C1(C2=NC=CC=C2)CCC2(CC1)NCCC1=C2NC2=CC=CC=C21 Chemical compound CN(C)C1(C2=NC=CC=C2)CCC2(CC1)NCCC1=C2NC2=CC=CC=C21 XGZFPMKIFPFGTB-UHFFFAOYSA-N 0.000 description 1
- RPIRUAJBQPCWNW-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(C(F)(F)F)C=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(C(F)(F)F)C=CC=C2)C2=C(C=CC=C2)C1 RPIRUAJBQPCWNW-UHFFFAOYSA-N 0.000 description 1
- DPCQWDVEMUIUAP-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2)C2=C(C=CC=C2)C1 DPCQWDVEMUIUAP-UHFFFAOYSA-N 0.000 description 1
- TXWNMYIWXULSST-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC(F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC(F)=C2)C2=C(C=CC=C2)C1 TXWNMYIWXULSST-UHFFFAOYSA-N 0.000 description 1
- RLHMMKBHGHJBAB-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2C(F)(F)F)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2C(F)(F)F)C2=C(C=CC=C2)C1 RLHMMKBHGHJBAB-UHFFFAOYSA-N 0.000 description 1
- SMZBGPLHEJFAJD-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2F)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C=CC=C2F)C2=C(C=CC=C2)C1 SMZBGPLHEJFAJD-UHFFFAOYSA-N 0.000 description 1
- NIDTVQPHDDIHIL-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C([N+](=O)[O-])C=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C([N+](=O)[O-])C=CC=C2)C2=C(C=CC=C2)C1 NIDTVQPHDDIHIL-UHFFFAOYSA-N 0.000 description 1
- ZFYADEZINHTIKU-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC(F)=CC(C(F)(F)F)=C2)C2=C(C=CC=C2)C1 ZFYADEZINHTIKU-UHFFFAOYSA-N 0.000 description 1
- LEEPHKCKRSNNQW-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC([N+](=O)[O-])=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC([N+](=O)[O-])=CC=C2)C2=C(C=CC=C2)C1 LEEPHKCKRSNNQW-UHFFFAOYSA-N 0.000 description 1
- FVYKIGIJWPDVRH-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(C(C)(C)C)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(C(C)(C)C)C=C2)C2=C(C=CC=C2)C1 FVYKIGIJWPDVRH-UHFFFAOYSA-N 0.000 description 1
- KNSXOUVXVUOZAH-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(C(F)(F)F)C=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=C(C(F)(F)F)C=C2)C2=C(C=CC=C2)C1 KNSXOUVXVUOZAH-UHFFFAOYSA-N 0.000 description 1
- ABUADRNDQVFJHQ-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CO2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=CC=CO2)C2=C(C=CC=C2)C1 ABUADRNDQVFJHQ-UHFFFAOYSA-N 0.000 description 1
- DUSMFSJWRFDHPG-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCC2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCC2)C2=C(C=CC=C2)C1 DUSMFSJWRFDHPG-UHFFFAOYSA-N 0.000 description 1
- FLNWTIZIGGMZNI-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCCCC2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2CCCCC2)C2=C(C=CC=C2)C1 FLNWTIZIGGMZNI-UHFFFAOYSA-N 0.000 description 1
- TWUCCXHKQVMLHI-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CC=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CC=C2)C2=C(C=CC=C2)C1 TWUCCXHKQVMLHI-UHFFFAOYSA-N 0.000 description 1
- COAIPXZXDRHHLU-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CS2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)CC2=CC=CS2)C2=C(C=CC=C2)C1 COAIPXZXDRHHLU-UHFFFAOYSA-N 0.000 description 1
- XPOHRPISGJWNOS-UHFFFAOYSA-N CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC=C2 Chemical compound CN(C)C1(CC2=CC=CC=C2)CCC2(CC1)NCCC1=C2NC2=C1C=CC=C2 XPOHRPISGJWNOS-UHFFFAOYSA-N 0.000 description 1
- SFJAWHZCZVBOKL-UHFFFAOYSA-N CN(C)C1(CCC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CCC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2)C2=C(C=CC=C2)C1 SFJAWHZCZVBOKL-UHFFFAOYSA-N 0.000 description 1
- HACXTPMJLXKCGL-UHFFFAOYSA-N CN(C)C1(CCC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2F)C2=C(C=CC=C2)C1 Chemical compound CN(C)C1(CCC2=CC=CC=C2)CCC2(CC1)C1=C(CCN2C(=O)C2=C(F)C(F)=C(F)C(F)=C2F)C2=C(C=CC=C2)C1 HACXTPMJLXKCGL-UHFFFAOYSA-N 0.000 description 1
- HVSGERDBEHZJAP-UHFFFAOYSA-N CNC1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(Cl)C(Cl)=C2 Chemical compound CNC1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(Cl)C(Cl)=C2 HVSGERDBEHZJAP-UHFFFAOYSA-N 0.000 description 1
- AMXGKMSRYLZAEO-UHFFFAOYSA-N CNC1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 Chemical compound CNC1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 AMXGKMSRYLZAEO-UHFFFAOYSA-N 0.000 description 1
- DUPJRUHMRBHETL-UHFFFAOYSA-N CNC1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(OC)C=C2 Chemical compound CNC1(C2=CC=CC=C2)CCC2(CC1)OCCC1=C2NC2=C1C=C(OC)C=C2 DUPJRUHMRBHETL-UHFFFAOYSA-N 0.000 description 1
- XJZNXLAQCSXKFH-UHFFFAOYSA-N CNC1(C2=CC=CS2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 Chemical compound CNC1(C2=CC=CS2)CCC2(CC1)OCCC1=C2NC2=C1C=C(F)C=C2 XJZNXLAQCSXKFH-UHFFFAOYSA-N 0.000 description 1
- CWYJZSOOUKNSOH-UHFFFAOYSA-N CNC1(C2=CC=CS2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 Chemical compound CNC1(C2=CC=CS2)CCC2(CC1)OCCC1=C2NC2=C1C=CC=C2 CWYJZSOOUKNSOH-UHFFFAOYSA-N 0.000 description 1
- VZRMEAXVAVUYJX-UHFFFAOYSA-N COC(=O)C1=CC2=C(C=C1)NC1=C2CCOC12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound COC(=O)C1=CC2=C(C=C1)NC1=C2CCOC12CCC(C1=CC=CC=C1)(N(C)C)CC2 VZRMEAXVAVUYJX-UHFFFAOYSA-N 0.000 description 1
- CZQBNOHBOCWDNO-UHFFFAOYSA-N COC(=O)CCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2 Chemical compound COC(=O)CCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2 CZQBNOHBOCWDNO-UHFFFAOYSA-N 0.000 description 1
- QHQIVCKAUOJRPU-UHFFFAOYSA-N COC(=O)CCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(CC1=CC=CC=C1)(N(C)C)CC2 Chemical compound COC(=O)CCC(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(CC1=CC=CC=C1)(N(C)C)CC2 QHQIVCKAUOJRPU-UHFFFAOYSA-N 0.000 description 1
- JPMIPUKFXJQABQ-UHFFFAOYSA-N COC1=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)C=CC=C1 Chemical compound COC1=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)C=CC=C1 JPMIPUKFXJQABQ-UHFFFAOYSA-N 0.000 description 1
- OLHFYCCPWSSNFK-UHFFFAOYSA-N COC1=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC=CC=C2)(N(C)C)CC3)C=CC=C1 Chemical compound COC1=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC=CC=C2)(N(C)C)CC3)C=CC=C1 OLHFYCCPWSSNFK-UHFFFAOYSA-N 0.000 description 1
- GTDZAQXXZAHUDH-UHFFFAOYSA-N COC1=CC(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)=CC(OC)=C1OC Chemical compound COC1=CC(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)=CC(OC)=C1OC GTDZAQXXZAHUDH-UHFFFAOYSA-N 0.000 description 1
- UBVSECOBZQYCMV-UHFFFAOYSA-N COC1=CC2=C(C=C1)NC1=C2CCOC12CCC(C1=CC=CC=C1)(N(C)C)CC2 Chemical compound COC1=CC2=C(C=C1)NC1=C2CCOC12CCC(C1=CC=CC=C1)(N(C)C)CC2 UBVSECOBZQYCMV-UHFFFAOYSA-N 0.000 description 1
- ITTPXADMYOZFKS-UHFFFAOYSA-N COC1=CC=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)C=C1 Chemical compound COC1=CC=C(C(=O)N2CCC3=C(CC4=C3C=CC=C4)C23CCC(C2=CC(F)=CC=C2)(N(C)C)CC3)C=C1 ITTPXADMYOZFKS-UHFFFAOYSA-N 0.000 description 1
- DUQLKGFEXZLMCD-UHFFFAOYSA-N Cc1ccccc1C(N(CC1)C(CC2)(CCC2(c2cc(F)ccc2)N(C)C)c2c1c(cccc1)c1[nH]2)=O Chemical compound Cc1ccccc1C(N(CC1)C(CC2)(CCC2(c2cc(F)ccc2)N(C)C)c2c1c(cccc1)c1[nH]2)=O DUQLKGFEXZLMCD-UHFFFAOYSA-N 0.000 description 1
- 0 [1*]N([2*])C1([3*])CCC2(CC1)CC([5*])C([6*])C1=C2[W]C2=C1C([7*])=C([8*])C([9*])=C2[10*] Chemical compound [1*]N([2*])C1([3*])CCC2(CC1)CC([5*])C([6*])C1=C2[W]C2=C1C([7*])=C([8*])C([9*])=C2[10*] 0.000 description 1
- DPALRBPGRVIHKQ-FOCLMDBBSA-N [H]/C(C(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2)=C(/[H])C1=CC=CC=C1 Chemical compound [H]/C(C(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(C1=CC(F)=CC=C1)(N(C)C)CC2)=C(/[H])C1=CC=CC=C1 DPALRBPGRVIHKQ-FOCLMDBBSA-N 0.000 description 1
- LEVAAZCFJCOAHN-ISLYRVAYSA-N [H]/C(C(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(CC1=CC=CC=C1)(N(C)C)CC2)=C(/[H])C1=CC=CC=C1 Chemical compound [H]/C(C(=O)N1CCC2=C(CC3=C2C=CC=C3)C12CCC(CC1=CC=CC=C1)(N(C)C)CC2)=C(/[H])C1=CC=CC=C1 LEVAAZCFJCOAHN-ISLYRVAYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Definitions
- Opiate dependency is a major medical and social problem, which requires intensive medical care.
- a standard treatment is opiate substitution by a specially suitable ⁇ -opioid.
- Clinically established substances for the substitution therapy of opiate dependency are:
- the object of the present invention was to provide a new method of treating substance dependence with substitution therapeutic agents.
- Another object of the invention is to provide a method of treating opioid dependency which has advantages compared to the standard therapies.
- the term salt is understood to denote any form of the active constituent according to the invention in which this adopts an ionic form or is charged, and is coupled to a counter-ion (a cation or anion) and/or is present in solution.
- the term is also understood to include complexes of the active constituent with other molecules and ions, in particular complexes which are complexed via ionic interactions.
- the term is understood to include (and this is also a preferred embodiment of the present invention) physiologically compatible salts, in particular physiologically compatible salts with cations or bases and physiologically compatible salts with anions or acids or also a salt formed with a physiologically compatible acid or with a physiologically compatible cation.
- salt formed with a physiologically compatible acid is understood within the context of the present invention to denote salts of the respective active constituent with inorganic or organic acids, which are physiologically compatible—especially when used in humans and/or mammals.
- the hydrochloride and citrate are particularly preferred.
- physiologically compatible acids are: hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutanic acid, 1,1-dioxo-1,2-dihydro1 ⁇ 6 -benzo[d]isothiazol-3-one (saccharinic acid), monomethylsebacic acid, 5-oxoproline, hexane-1-sulfonic acid, nicotinic acid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethylbenzoic acid, ⁇ -lipoic acid, acetylglycine, hippuric acid and/or aspartic acid.
- C 1-3 -alkyl “C 1-5 -alkyl”, “C 1-7 -alkyl” and “C 1-4 -alkyl” include acyclic saturated or unsaturated hydrocarbon radicals, which may be branched or straight-chain, with respectively 1, 2 or 3 C atoms, 1, 2, 3, 4 or 5 C atoms, 1, 2, 3, 4, 5, 6 or 7 C atoms or 1, 2, 3 or 4 C atoms.
- Unsaturated compounds have at least one C—C double bond or at least one C—C triple bond.
- alkyl is advantageously selected, which includes methyl, ethyl, n-propyl, 2-propyl, n-butyl, iso-butyl, sec.-butyl, tert.-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl; ethylenyl (vinyl), ethinyl, propenyl (—CH 2 CH ⁇ CH 2 , —CH ⁇ CH—CH 3 , —C( ⁇ CH 2 )—CH 3 ), propinyl (—CH—C ⁇ CH, —C ⁇ C—CH 3 ), 1,1-dimethylethyl, 1,1-dimethylpropyl, butenyl, butinyl, pentenyl and pentinyl.
- C 5-6 -cycloalkyl denotes cyclic hydrocarbons with 5 or 6 Carbon atoms, wherein the hydrocarbons may be saturated or unsaturated (but not aromatic). From the above group C 5-6 -cycloalkyl is advantageously selected, which includes cyclopentyl and cyclohexyl.
- heteroaryl denotes a 5-, 6- or 7-membered cyclic aromatic radical, which contains at least 1, but possibly also 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are identical or different and the heterocycle may be unsubstituted or singly or multiply substituted; in the case of substitution in the heterocycle, the substituents may be identical or different and in any arbitrary and possible position of the heteroaryl.
- Preferred heteroatoms are nitrogen, oxygen and sulphur.
- heteroaryl radical from the group comprising pyrrolyl, furyl (furanyl), benzofuranyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridinyl, or carbazolyl, wherein the bonding to the compounds of the general structure I can be effected by any arbitrary and possible ring member of the heteroaryl radical.
- Pyridyl and thienyl are particularly preferred.
- Pyrazolyl and furyl are also particularly preferred.
- the compounds according to the invention have on account of the ORL1 active component additional properties which the standard substances such as methadone, LAAM or buprenorphine do not possess and which improve the treatment.
- the ORL1 active component In withdrawal jumping in mice it was shown that in the case of mice that had been treated with combined ⁇ -/ORL1 agonists, as in Example 1, Example 3 or Example 4, no, or only a minimal, withdrawal behaviour is triggered by naloxone. This confirms that the withdrawal symptoms are suppressed by the ORL1 component. This results in a significant advantage if these substances are used in the treatment of withdrawal symptoms, since the occurrence of withdrawal symptoms is one of the most important side effects of this treatment and often leads to non-compliance.
- the ORL1/ ⁇ -affinity should be 0.3 or greater. It is preferred if the ORL1/ ⁇ -affinity ratio is ⁇ 1, particularly preferably ⁇ 1.7.
- the substance dependency is opiate dependency, for example dependency on alfentanil, buprenorphine, butorphanol, codeine, dextromoramide, dextropropoxyphene, dezocin, dihydrocodeine, diphenoxylate, ethylmorphine, hydrocodone, hydromorphone, ketobemidone, LAAM, levorphanol, meptazinol, oxycodon, oxymorphone, fentanyl, morphine, heroin, pethidine, sufentanil or tilidin, preferably morphine, methadone or heroin.
- opiate dependency for example dependency on alfentanil, buprenorphine, butorphanol, codeine, dextromoramide, dextropropoxyphene, dezocin, dihydrocodeine, diphenoxylate, ethylmorphine, hydrocodone, hydromorphone, ketobemidone, LAAM, levorphanol, mept
- the spirocyclic cyclohexane derivatives according to the invention can also be used in combination with an opioid receptor antagonist, preferably with naloxone.
- Spirocyclic cyclohexane derivatives in which R 3 denotes heteroaryl are preferred in the context of the present invention. Also preferred in the context of the present invention are spirocyclic cyclohexane derivatives in which R 3 denotes phenyl, unsubstituted or singly or multiply substituted with F, OH, Cl or OCH 3 , or denotes benzyl.
- R 1 and R 2 denote CH 3 or H, in which case R 1 and R 2 do not simultaneously denote H.
- spirocyclic cyclohexane derivatives selected from the group:
- Particularly preferred compounds are selected from the group consisting of:
- spirocyclic cyclohexane derivatives in which W denotes NR 4 and X denotes O are likewise particularly preferred. Accordingly, in the context of the present invention spirocyclic cyclohexane derivatives in which W denotes NR 4 and X denotes O are preferred. It is particularly preferred to use compounds selected from the group consisting of:
- solvent for example methanol/ethyl acetate was used in a ratio of 1:1, 2:1, 3:1 or 4:1, preferably 3:1, or methanol/conc. ammonia solution 99.5:0.5 or methanol/ethyl acetate/conc. ammonia solution in a ratio of 66:33:0.5.
- compositions of the invention optionally contain, besides at least one compound according to the invention, suitable additives and/or auxiliary substances, including carrier materials, fillers, solvents, diluents, coloring agents and/or binders, and may be administered as liquid medicament forms in the form of injection solutions, drops or ointments, as semi-solid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray plasters or aerosols.
- suitable additives and/or auxiliary substances including carrier materials, fillers, solvents, diluents, coloring agents and/or binders, and may be administered as liquid medicament forms in the form of injection solutions, drops or ointments, as semi-solid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray plasters or aerosols.
- suitable additives and/or auxiliary substances including carrier materials, fillers, solvents, diluents, coloring agents and/or binders
- suitable preparations are in the form of tablets, coated tablets, capsules, granules, drops, ointments and syrups, while for parenteral, topical and inhalative application suitable forms are solutions, suspensions, readily reconstitutable dry preparations, as well as sprays.
- Spirocyclic cyclohexane derivatives according to the invention in depot form, in dissolved form or in a plaster form, optionally with the addition of agents promoting penetration of the skin, are suitable percutaneous application preparations.
- Orally or percutaneously usable preparation forms can provide for the delayed release of the compounds according to the invention.
- the compounds according to the invention can also be employed in parenteral long-term depot forms, such as for example implants or implanted pumps. In principle other active constituents known to the person skilled in the art can be added to the medicaments according to the invention.
- the amount of active constituent to be administered to the patient varies depending on the patient's weight, form of application, medical implications and the severity of the illness. Normally 0.00005 to 1 mg/kg, preferably 0.0001 to 0.05 mg/kg of at least one spirocyclic cyclohexane derivative according to the invention is applied.
- All the aforementioned forms of the medicaments according to the invention also may contain, in addition to at least one compound according to the invention, a further active constituent, in particular an opioid antagonist, preferably naloxone.
- a further active constituent in particular an opioid antagonist, preferably naloxone.
- levomethadone which has no significant ORL1 component
- Levomethadone which is one of the standard therapeutic agents used in substitution therapy, likewise induced withdrawal jumping.
- compounds described in US 2006/004034 A1 and US 2005/066183 A1 are a number of substances with a slight ORL1 component.
- Two typical members with a slight ORL1 component (compounds m and n) were likewise tested in the withdrawal jumping test and induced withdrawal jumping. This shows the importance of the ORL1 component as regards the suitability of a substance for substitution therapy within the group of compounds described in US 2006/004034 A1 and US 2005/066183 A1.
- the compounds according to the invention show significantly reduced cardiovascular side effects compared to methadone and LAAM.
- the cardiovascular side effects are attributed to a delayed cardiac repolarisation (manifested as a QTc extension in the outside ECG), which is caused by the blockade of a special potassium channel (HERG) (Kornick et al. Pain 2003, 105, 499-506).
- HERG special potassium channel
- Both methadone and LAAM exhibit interactions with the HERG channel (Jiesheng et al., Eur. J. Pharmacol. 2003, 458, 25-29; Katchman et al., J. Pharmacol. Exp. Ther. 2002, 303, 688-694).
- the cyclohexane derivatives of the general formula I were investigated in a receptor binding assay with 3 H-nociceptin/orphanin FQ with membranes of recombinant CHO-ORL1 cells.
- This test system was implemented according to the method proposed by Ardati et al. (Mol. Pharmacol., 51, 1997, pp. 816-824).
- the concentration of 3H-nociceptin/orphanin FQ in these tests was 0.5 nM.
- the binding assays were carried out with 20 ⁇ g of membrane protein per 200 ⁇ l of batch in 50 mM Hepes, pH 7.4, 10 mM MgCl 2 and 1 mM EDTA.
- the binding to the ORL1 receptor was determined using in each case 1 mg WGA-SPA beads (Amersham-Pharmacia, Freiburg), by incubating the batch for one hour at room temperature followed by measurement in a Trilux scintillation counter (Wallac, Finland).
- the receptor affinity for the human ⁇ -opiate receptor was determined in a homogeneous batch in mikrotiter plates. For this purpose dilution series of the respective substituted cyclohexyl-1,4-diamine derivatives to be tested were incubated with a receptor membrane preparation (15-40 ⁇ g protein per 250 ⁇ l incubation batch) of CHO—K1 cells which express the human ⁇ -opiate receptor (RB-HOM receptor membrane preparation obtained from the NEN company, Zaventem, Belgium) in the presence of 1 nmol/1 of the radioactive ligand [3H]-naloxone (NET719, NEN company, Zaventem, Belgium) as well as of 1 mg WGA-SPA beads (wheat germ agglutinin SPA Beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 ⁇ l for 90 minutes at room temperature.
- a receptor membrane preparation 15-40 ⁇ g protein per 250 ⁇ l incubation batch
- the percentage displacement of the radioactive ligand from its binding to the human ⁇ -opiate receptor at a concentration of the test substances of 1 ⁇ mol/l was determined and given as the percentage inhibition (% inhibition) of the specific binding.
- IC 50 inhibition concentrations which effect a 50% displacement of the radioactive ligand were calculated on the basis of the percentage displacement by different concentration of the compounds of the general formula I to be tested. Ki values for the test substances were obtained by conversion using the Cheng-Prusoff relationship.
- test substances were applied intraperitoneally a total of seven times over two days. Five applications were made on the first day at 9:00, 10:00, 11:00, 13:00 and 15:00 hours, and on the second day at 9:00 and 11:00 hours. The first three applications were made in increasing dosages (dosage scheme), the further applications being at the dosage of the third application.
- the withdrawal symptoms were triggered with 30 mg/kg naloxone (i.p.) two hours after the last substance application. Immediately following this the animals were placed individually in transparent observation cages (height 40 cm, diameter 15 cm) and the jumping reactions were counted over 15 minutes in 5-minute periods in each case. Morphine was administered in a dosage as comparison/standard.
- the withdrawal symptoms were quantified by counting the number of jumps over 0 to 10 minutes after application of naloxone. The number of animals per group exhibiting more than 10 jumps/10 minutes was determined and recorded as “% positive animals”. The average jumping frequency in the group was also calculated. Twelve animals were used per group.
- FIG. 1 is a graph of the mice jumping test results for levomethadone
- FIG. 2 is a graph of the jumping test results for compound m
- FIG. 3 is a graph of the jumping test results for compound n
- FIG. 4 is a graph of the jumping test results according to Example 1.
- FIG. 5 is a graph of the jumping test results according to Example 3.
- FIG. 6 is a graph of the jumping test results according to Example 4.
- the electrocardiogram measurement was carried out as a bipolar limb lead according to Einthoven (lead II).
- the Beagle dogs were placed in a special hammock-like holder (Animal sling, Havard Instruments, ZAK, Tidenfeld, Germany) and loosely secured.
- a measurement electrode was applied to each of the left and right front limbs, and a reference electrode was also applied to the rear limb. All electrodes were plate electrodes, which were fixed to the shaved skin by rubber collars.
- the plate electrodes were connected to a ECG pre-amplifier and the signals were continuously digitised by means of a computer-controlled data receiving and archiving system (PO-NE-MAH, Gould-Instrument Systems, USA) (digitising frequency: 2 kHz).
- PO-NE-MAH Gould-Instrument Systems, USA
- the mean values of the following parameters were determined from 10 successive ECG intervals per measurement time: RR interval, PR interval, QRS interval and QT interval.
- the frequency correction of the QT interval was made according to the correction formula of Van de Water et al. (1989).
- Each of the test substances was administered as an i.v. short infusion (15 minutes) via the V. cephalica antibrachii.
- the changes in the ECG parameters over a period of 60 minutes after administration of the substance were recorded relative to the base value before administration of the substance.
- the statistical evaluation was carried out by means of variance analysis (ANOVA) compared to synchronous vehicle control measurements. (Van de Water A, Verheyen J, Xhonneux R, Reneman R S. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods. 1989 November; 22(3):207-17).
- the IC 50 value for LAAM is 2 ⁇ m (interactions of LAAM/HERG channel, see Jiesheng et al., Eur. J. Pharmacol. 2003, 458, 25-29), the IC 50 value for methadone is 9.8 ⁇ M (see Katchman et al., J. Pharmacol. Exp. Ther. 2002, 303, 688-694).
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency.
Description
- This application is continuation of U.S. application Ser. No. 11/870,051, filed Oct. 10, 2007, which claims priority from international patent application no. PCT/EP2006/003176, filed Apr. 7, 2006, designating the United States of America, and published in German on Oct. 19, 2006 as WO 2006/108565, the entire disclosure of which is incorporated herein by reference. Priority is claimed based on Federal Republic of Germany Patent Application No. DE 10 2005 016 460.9, filed Apr. 11, 2005.
- Opiate dependency is a major medical and social problem, which requires intensive medical care. A standard treatment is opiate substitution by a specially suitable μ-opioid. Clinically established substances for the substitution therapy of opiate dependency are:
-
- methadone (racemate, in rare cases levomethadone)
- LAAM (α-acetylmethadol)
- buprenorphine
All three substances are used to achieve the same objectives: - satisfaction of the opiate craving but without any “kick” and with a significantly reduced euphoria
- avoidance of bodily withdrawal symptoms
- re-socialisation of the patient (controlled rehabilitation, ability to work, withdrawal from the drug-related environment)
- long-term reduction in the opiate dosage until complete abstinence is achieved.
In order that these effects can be achieved, the substitution therapeutic agents must have the following properties: - oral (possibly also cutaneous) effect availability
- long effective duration (1-3 days, possibly even longer)
- high potency
- low euphorisation
- low “kick”
- low withdrawal symptoms
- good long-term compatibility (only slight constipation, good cardiovascular compatibility)
The standard therapeutic agents used up to now exhibit only some of these properties, with the result that their therapeutic use is to some extent unsatisfactory. The basic problems with the current standard therapeutic agents are the following: methadone has a high potential for misuse. On account of the only moderate action duration a daily administration is necessary. In addition constipation is a side effect. LAAM has the disadvantage of a high cardiotoxicity and can trigger Torsade de Pointes arrhythmia. Buprenorphine has a high toxicity when combined with benzodiazepines.
- US 2006/004034 A1 (=WO 04/43967) and US 2005/192333 A1 (=WO 2005/066183) describe compounds that are particularly suitable for the treatment of pain, but also inter alia for the treatment of withdrawal symptoms as well as for reducing the potential for opioid addiction. It has now been found that that selected compounds from these patent applications are particularly suitable for use as substitution therapeutic agents in treatment of substance dependence.
- The object of the present invention was to provide a new method of treating substance dependence with substitution therapeutic agents.
- Another object of the invention is to provide a method of treating opioid dependency which has advantages compared to the standard therapies.
- These and other objects have been achieved in accordance with the present invention by providing spirocyclic cyclohexane compounds corresponding to formula I
-
- wherein
- R1 and R2 independently of one another denote H or CH3 or together denote (CH2)4 or (CH2)5 and form a ring with the nitrogen to which they are bound, wherein R1 and R2 do not simultaneously denote H;
- R3 denotes phenyl, benzyl or heteroaryl in each case unsubstituted or singly or multiply substituted with F, Cl, OH, CN or OCH3;
- W denotes NR4, O or S, where
- R4 denotes H; C1-5-alkyl, phenyl; phenyl, COR12 bound via a C1-3-alkyl group;
- SO2R12, where
- R12 denotes H; C1-7-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or singly or multiply substituted with OH, F or COOC1-4-alkyl; C4-6-cycloalkyl; aryl or heteroaryl, unsubstituted or singly or multiply substituted with F, Cl, Br, CF3, OCH3, C1-4-alkyl, branched or unbranched, substituted; or phenyl or heteroaryl bound via saturated or unsaturated C1-3 alkyl, unsubstituted or singly or multiply substituted with F, Cl, Br, CF3, OCH3, C1-4-alkyl, branched or unbranched, substituted; or C5-6-cycloalkyl bound via saturated or unsaturated C1-3-alkyl; OR13; NR14R15;
- R4 denotes H; C1-5-alkyl, phenyl; phenyl, COR12 bound via a C1-3-alkyl group;
- R5 denotes H; COOR13, CONR13, OR13; C1-5-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or singly or multiply substituted with OH, F, CF3 or CN;
- R6 denotes H; or
- R5 and R6 together denote (CH2)n where n=2, 3, 4, 5 or 6, wherein individual hydrogen atoms may also be replaced by F, Cl, NO2, CF3, OR13, CN or C1-5-alkyl;
- R7, R8, R9 and R10 independently of one another denote H, F, Cl, Br, NO2, CF3, OH, OCH3, CN, COOR13, NR14R15; C1-5-alkyl, heteroaryl, unsubstituted or singly or multiply substituted with benzyl, CH3, Cl, F, OCH3 or OH; where
- R13 denotes H or C1-5-alkyl; and
- R14 and R15 independently of one another denote H or C1-5-alkyl;
- X denotes 0, S, SO, SO2 or NR17; where
- R17 denotes H; C1-5-alkyl, saturated or unsaturated, branched or unbranched; COR12 or SO2R12,
in the form of their pure diastereomers, their racemates, their pure enantiomers, or in the form of mixtures of the stereoisomers in an arbitrary mixture ratio; as bases or in the form of their salts, in particular of the physiologically compatible salts or salts of physiological compatible acids or cations; or in the form of their solvates,
wherein the ratio of the ORL1 receptor affinity to the μ-opioid receptor affinity is 0.3 or greater, for the treatment of substance dependency.
- R17 denotes H; C1-5-alkyl, saturated or unsaturated, branched or unbranched; COR12 or SO2R12,
- As used herein, the term salt is understood to denote any form of the active constituent according to the invention in which this adopts an ionic form or is charged, and is coupled to a counter-ion (a cation or anion) and/or is present in solution. The term is also understood to include complexes of the active constituent with other molecules and ions, in particular complexes which are complexed via ionic interactions. In particular the term is understood to include (and this is also a preferred embodiment of the present invention) physiologically compatible salts, in particular physiologically compatible salts with cations or bases and physiologically compatible salts with anions or acids or also a salt formed with a physiologically compatible acid or with a physiologically compatible cation.
- The term salt formed with a physiologically compatible acid is understood within the context of the present invention to denote salts of the respective active constituent with inorganic or organic acids, which are physiologically compatible—especially when used in humans and/or mammals. The hydrochloride and citrate are particularly preferred. Examples of physiologically compatible acids are: hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutanic acid, 1,1-dioxo-1,2-dihydro1λ6-benzo[d]isothiazol-3-one (saccharinic acid), monomethylsebacic acid, 5-oxoproline, hexane-1-sulfonic acid, nicotinic acid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethylbenzoic acid, α-lipoic acid, acetylglycine, hippuric acid and/or aspartic acid.
- In the context of the present invention, the expressions “C1-3-alkyl” “C1-5-alkyl”, “C1-7-alkyl” and “C1-4-alkyl” include acyclic saturated or unsaturated hydrocarbon radicals, which may be branched or straight-chain, with respectively 1, 2 or 3 C atoms, 1, 2, 3, 4 or 5 C atoms, 1, 2, 3, 4, 5, 6 or 7 C atoms or 1, 2, 3 or 4 C atoms. Unsaturated compounds have at least one C—C double bond or at least one C—C triple bond. From the above group alkyl is advantageously selected, which includes methyl, ethyl, n-propyl, 2-propyl, n-butyl, iso-butyl, sec.-butyl, tert.-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl; ethylenyl (vinyl), ethinyl, propenyl (—CH2CH═CH2, —CH═CH—CH3, —C(═CH2)—CH3), propinyl (—CH—C≡CH, —C≡C—CH3), 1,1-dimethylethyl, 1,1-dimethylpropyl, butenyl, butinyl, pentenyl and pentinyl.
- For the purposes of the present invention, the expression “C5-6-cycloalkyl” denotes cyclic hydrocarbons with 5 or 6 Carbon atoms, wherein the hydrocarbons may be saturated or unsaturated (but not aromatic). From the above group C5-6-cycloalkyl is advantageously selected, which includes cyclopentyl and cyclohexyl.
- The expression “heteroaryl” denotes a 5-, 6- or 7-membered cyclic aromatic radical, which contains at least 1, but possibly also 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are identical or different and the heterocycle may be unsubstituted or singly or multiply substituted; in the case of substitution in the heterocycle, the substituents may be identical or different and in any arbitrary and possible position of the heteroaryl. Preferred heteroatoms are nitrogen, oxygen and sulphur. It is preferred to select the heteroaryl radical from the group comprising pyrrolyl, furyl (furanyl), benzofuranyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridinyl, or carbazolyl, wherein the bonding to the compounds of the general structure I can be effected by any arbitrary and possible ring member of the heteroaryl radical. Pyridyl and thienyl are particularly preferred. Pyrazolyl and furyl are also particularly preferred.
- Animal experiment investigations with substances from US 2006/004034 A1 and US 2005/192333 A1 have surprisingly shown that the substances with a particularly high ORL1 affinity, which is not more than one order of magnitude less than the μ-opioid receptor affinity, are particularly suitable for an opiate substitution and thus have the potential for a significant improvement in the substitution therapy.
- Among the spiro compounds described in US 2006/004034 A1 and US 2005/066183 A1 are compounds with higher and lower ORL1 components. In naloxone-induced withdrawal symptoms in mice it was shown that spirocyclic compounds with an ORL1 component which is not weaker by a factor of more than 10 than the μ-component, can suppress withdrawal symptoms. Compounds with a weaker ORL1 component on the other hand trigger withdrawal symptoms. In the “withdrawal jumping” test mice are repeatedly treated over a defined period with the test substance. In the case of a μ-opioid a systemic dependency is induced within this period. At the end of the treatment the effect of the opioid is cancelled immediately by administering naloxone, a μ-antagonist. When the mice become systemically dependent they exhibit characteristic withdrawal symptoms, which are manifested in the form of jumping movements (Saelens J K, Arch Int Pharmacodyn 190: 213-218, 1971).
- The compounds according to the invention have on account of the ORL1 active component additional properties which the standard substances such as methadone, LAAM or buprenorphine do not possess and which improve the treatment. In withdrawal jumping in mice it was shown that in the case of mice that had been treated with combined μ-/ORL1 agonists, as in Example 1, Example 3 or Example 4, no, or only a minimal, withdrawal behaviour is triggered by naloxone. This confirms that the withdrawal symptoms are suppressed by the ORL1 component. This results in a significant advantage if these substances are used in the treatment of withdrawal symptoms, since the occurrence of withdrawal symptoms is one of the most important side effects of this treatment and often leads to non-compliance. The ORL1/μ-affinity should be 0.3 or greater. It is preferred if the ORL1/μ-affinity ratio is ≧1, particularly preferably ≧1.7.
- The result that the compounds according to the invention with a stronger ORL1 component suppress the withdrawal jumping that should be triggered by the μ-component, demonstrates the efficacy of these compounds for use in substitution therapy. It is therefore preferred if the substance dependency is opiate dependency, for example dependency on alfentanil, buprenorphine, butorphanol, codeine, dextromoramide, dextropropoxyphene, dezocin, dihydrocodeine, diphenoxylate, ethylmorphine, hydrocodone, hydromorphone, ketobemidone, LAAM, levorphanol, meptazinol, oxycodon, oxymorphone, fentanyl, morphine, heroin, pethidine, sufentanil or tilidin, preferably morphine, methadone or heroin.
- The spirocyclic cyclohexane derivatives according to the invention can also be used in combination with an opioid receptor antagonist, preferably with naloxone.
- In the synthesis of the compounds according to the invention, as described in US 2006/004034 A1 and US 2005/066183 A1, two or more diastereomers can occur. In most cases the non-polar diastereomers have compared to the polar diastereomers a higher affinity for the two investigated opiate receptors. It is therefore preferred if the substances according to the invention are present in the form of the non-polar diastereomer.
- Spirocyclic cyclohexane derivatives in which R3 denotes heteroaryl are preferred in the context of the present invention. Also preferred in the context of the present invention are spirocyclic cyclohexane derivatives in which R3 denotes phenyl, unsubstituted or singly or multiply substituted with F, OH, Cl or OCH3, or denotes benzyl.
- Also preferred are spirocyclic cyclohexane derivatives in which R1 and R2 denote CH3 or H, in which case R1 and R2 do not simultaneously denote H.
- It is preferred to use spirocyclic cyclohexane derivatives selected from the group:
- 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 2 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2-nitrobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 3 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 4 1,1-(3-dimethylamino-3-(2-thienyl)pentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 5 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 6 1,1-(3-dimethylamino-3-phenylpentamethylene)-3,6-dimethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 7 1,1-(3-dimethylamino-3-(4-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 8 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-hydroxymethyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 9 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,3,4,5,6-pentafluoro-benzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 10 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(methoxycarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 11 1,1-(3-dimethylamino-3-phenylpentamethylene)-7-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 12 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-aza-9-oxafluorene;
- 13 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 14 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-acetyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 15 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 16 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-chloro-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 17 1,1-(3-dimethylamino-3-(2-pyridyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 18 1,1-(3-dimethylamino-3-(3-thienyl)pentamethylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 19 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-acetyl-7-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 20 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 21 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetra-hydropyrano[3,4-b]indole;
- 22 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-thia-9-azafluorene;
- 23 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-6-nitro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 24 1,1-(3-dimethylamino-3-(3-thienyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 25 1,1-(3-dimethylamino-3-(4-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 26 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 27 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-oxo-1,3,4,9-tetrahydro-2-thia-9-azafluorene;
- 28 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-thia-9-azafluorene;
- 29 1,1-(3-dimethylamino-3-(2-thienyl)pentamethylene)-6-fluoro-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 30 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 31 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 32 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-hydroxy-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 33 1,1-(3-dimethylamino-3-(3-hydroxyphenyl)pentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 34 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-thia-9-azafluorene;
- 35 6,6-(3-dimethylamino-3-phenylpentamethylene)-1,2,3,4,4a,6,7,11c-octahydro-5-oxa-7-aza-benzo[c]fluorine;
- 36 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 37 1,1-(3-dimethylamino-3-(4-fluorophenyl)pentamethylene)-2-acetyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 38 1,1-(3-dimethylamino-3-benzylpentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 39 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 40 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-methyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 41 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-bromo-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 42 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 43 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-bromo-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 44 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-methoxy-1,3,4,9-tetra-hydropyrano[3,4-b]indole;
- 45 1,1-(3-(1-Pyrrolidyl)-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 46 1,1-(3-dimethylamino-3-phenylpentamethylene)-7,8-dichloro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 47 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-(1-benzyl-pyrazol-4-yl)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 48 1,1-(3-Methylamino-3-(2-thienyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 49 1,1-(3-methylamino-3-(2-thienyl)pentamethylene)-6-fluoro-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 50 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-cinnamoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 51 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,3-dimethylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 52 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(cyclopentylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 53 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,3-dimethylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 54 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(pentanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 55 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 56 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 57 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 58 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 59 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 60 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(cyclohexylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 61 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-benzoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 62 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(cyclohexylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 63 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 64 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 65 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 66 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(thien-2-ylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 67 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 68 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-butanoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 69 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 70 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 71 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,3-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 72 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 73 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-phenylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 74 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,4-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 75 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cinnamoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 76 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,6-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 77 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 78 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-chlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 79 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 80 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,6-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 81 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 82 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,3,4,5,6-pentafluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 83 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cyclohexylcarbonyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 84 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-cyclopentylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 85 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-fluoro-3-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 86 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 87 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4,5-trimethoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 88 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cyclobutylcarbonyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 89 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,6-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 90 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 91 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-thienylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 92 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-propanoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 93 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 94 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,5-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 95 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-tert.butylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 96 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 97 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 98 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-ethylhexanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 99 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 100 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-phenylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 101 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 102 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-fluoro-3-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 103 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-nitrobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 104 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,5-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 105 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 106 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 107 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-chlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 108 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 109 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,3,4,5-tetrafluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 110 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,6-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 111 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 112 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,4-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 113 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 114 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-chlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 115 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 116 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-fluoro-4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 117 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2-thienylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 118 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,6-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 119 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 120 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 121 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 122 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-fluoro-6-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 123 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 124 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,5-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 125 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 126 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(pentanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 127 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(6-fluoro-2-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 128 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 129 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(4-tert.butylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 130 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 131 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,5-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 132 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,3,4,5,6-pentafluoro-benzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 133 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-nitrobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 134 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-nitrobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 135 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,3,4,5-tetrafluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 136 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-thienylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 137 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-fluoro-4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 138 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 139 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(cyclobutylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 140 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 141 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,5-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 142 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-bromobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 143 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 144 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 145 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,3-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene, and
physiologically compatible salts thereof - It has been found that spirocyclic cyclohexane derivatives in which W denotes NR4 and X denotes NR17 are particularly advantageous. Accordingly it is preferred to use compounds in which R denotes NR4 and X denotes NR17. It is particularly preferred to use compounds selected from the group consisting of:
- 2 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2-nitrobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 8 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-hydroxymethyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 9 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,3,4,5,6-pentafluoro-benzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 10 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(methoxycarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 11 1,1-(3-dimethylamino-3-phenylpentamethylene)-7-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 13 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 14 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-acetyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 17 1,1-(3-dimethylamino-3-(2-pyridyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 19 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-acetyl-7-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 20 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 25 1,1-(3-dimethylamino-3-(4-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 26 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 30 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 37 1,1-(3-dimethylamino-3-(4-fluorophenyl)pentamethylene)-2-acetyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 38 1,1-(3-dimethylamino-3-benzylpentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 39 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 40 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-methyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 50 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-cinnamoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 51 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,3-dimethylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 52 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(cyclopentylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 53 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,3-dimethylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 54 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(pentanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 55 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 56 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 57 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 58 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 59 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 60 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(cyclohexylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 61 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-benzoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 62 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(cyclohexylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 63 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 64 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 65 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 66 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(thien-2-ylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 67 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 68 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-butanoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 69 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 70 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 71 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,3-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 72 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 73 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-phenylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 74 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,4-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 75 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cinnamoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 76 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,6-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 77 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 78 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-chlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 79 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 80 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,6-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 81 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 82 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,3,4,5,6-pentafluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 83 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cyclohexylcarbonyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 84 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-cyclopentylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 85 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-fluoro-3-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 86 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 87 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4,5-trimethoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 88 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cyclobutylcarbonyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 89 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,6-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 90 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 91 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-thienylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 92 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-propanoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 93 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 94 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,5-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 95 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-tert.butylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 96 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 97 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 98 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-ethylhexanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 99 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 100 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-phenylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 101 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 102 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-fluoro-3-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 103 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-nitrobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 104 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,5-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 105 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 106 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 107 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-chlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 108 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 109 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,3,4,5-tetrafluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 110 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,6-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 111 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 112 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,4-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 113 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 114 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-chlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 115 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 116 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-fluoro-4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 117 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2-thienylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 118 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,6-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 119 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 120 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 121 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 122 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-fluoro-6-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 123 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 124 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,5-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 125 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 126 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(pentanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 127 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(6-fluoro-2-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 128 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 129 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(4-tert.butylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 130 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 131 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,5-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 132 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,3,4,5,6-pentafluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 133 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-nitrobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 134 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-nitrobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 135 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,3,4,5-tetrafluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 136 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-thienylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 137 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-fluoro-4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 138 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 139 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(cyclobutylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 140 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 141 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,5-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 142 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-bromobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 143 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 144 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 145 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,3-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene, and
physiologically compatible salts thereof. - Particularly preferred compounds are selected from the group consisting of:
- 8 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-hydroxymethyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 10 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(methoxycarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 11 1,1-(3-dimethylamino-3-phenylpentamethylene)-7-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 13 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 14 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-acetyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 17 1,1-(3-dimethylamino-3-(2-pyridyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 19 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-acetyl-7-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 20 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 25 1,1-(3-dimethylamino-3-(4-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 50 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-cinnamoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 51 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,3-dimethylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 52 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(cyclopentylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 53 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,3-dimethylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 54 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(pentanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 55 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 56 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 57 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 58 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 59 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 60 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(cyclohexylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 61 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-benzoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 62 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(cyclohexylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 63 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 64 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 65 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 66 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(thien-2-ylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 67 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 68 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-butanoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 69 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 70 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 71 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,3-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 72 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 73 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-phenylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 74 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,4-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 75 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cinnamoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 76 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,6-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 77 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 78 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-chlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 79 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 80 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2,6-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 81 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 82 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,3,4,5,6-pentafluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 83 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cyclohexylcarbonyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 84 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-cyclopentylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 85 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-fluoro-3-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 86 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 87 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4,5-trimethoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 88 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-cyclobutylcarbonyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 89 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(2,6-dichlorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 90 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 91 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-thienylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 92 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-propanoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 93 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 94 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,5-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 95 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-tert.butylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 96 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-methoxycarbonylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 97 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,4-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 98 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-ethylhexanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 99 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 100 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-phenylpropanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 101 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 102 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-fluoro-3-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene; and
physiologically compatible salts thereof. - Particularly preferred are compounds selected from the group consisting of:
- 8 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-hydroxymethyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 10 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(methoxycarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 11 1,1-(3-dimethylamino-3-phenylpentamethylene)-7-fluoro-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 13 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 14 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-acetyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 17 1,1-(3-dimethylamino-3-(2-pyridyl)pentamethylene)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 50 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-cinnamoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 51 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(3,3-dimethylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 52 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(cyclopentylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 53 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3,3-dimethylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 54 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(pentanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 55 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 56 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(2-furylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 57 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-fluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 58 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 59 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(3-methylbutanoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 60 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(cyclohexylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 61 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-benzoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 62 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(cyclohexylcarbonyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 63 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 64 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methoxybenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 65 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-(4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 66 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(thien-2-ylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 67 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(phenylacetyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 68 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-butanoyl-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 69 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(4-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 70 1,1-(3-dimethylamino-3-benzylpentamethylene)-2-(3-fluoro-5-trifluoromethylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 71 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(2,3-difluorobenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene;
- 72 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-2-(4-methylbenzoyl)-1,3,4,9-tetrahydro-2,9-diazafluorene, and
physiologically acceptable salts thereof - Furthermore, is has been shown that spirocyclic cyclohexane derivatives in which W denotes NR4 and X denotes O are likewise particularly preferred. Accordingly, in the context of the present invention spirocyclic cyclohexane derivatives in which W denotes NR4 and X denotes O are preferred. It is particularly preferred to use compounds selected from the group consisting of:
- 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 3 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 4 1,1-(3-dimethylamino-3-(2-thienyl)pentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 5 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 6 1,1-(3-dimethylamino-3-phenylpentamethylene)-3,6-dimethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 7 1,1-(3-dimethylamino-3-(4-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 12 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-aza-9-oxafluorene;
- 15 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 16 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-chloro-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 18 1,1-(3-dimethylamino-3-(3-thienyl)pentamethylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 21 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetra-hydropyrano[3,4-b]indole;
- 23 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-6-nitro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 24 1,1-(3-dimethylamino-3-(3-thienyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 29 1,1-(3-dimethylamino-3-(2-thienyl)pentamethylene)-6-fluoro-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 31 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 32 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-hydroxy-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 33 1,1-(3-dimethylamino-3-(3-hydroxyphenyl)pentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 35 6,6-(3-dimethylamino-3-phenylpentamethylene)-1,2,3,4,4a,6,7,11c-octahydro-5-oxa-7-aza-benzo[c]fluorine;
- 36 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 41 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-bromo-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 42 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 43 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-bromo-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 44 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-methoxy-1,3,4,9-tetra-hydropyrano[3,4-b]indole;
- 45 1,1-(3-(1-Pyrrolidyl)-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 46 1,1-(3-dimethylamino-3-phenylpentamethylene)-7,8-dichloro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 47 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-(1-benzyl-pyrazol-4-yl)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 48 1,1-(3-Methylamino-3-(2-thienyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 49 1,1-(3-Methylamino-3-(2-thienyl)pentamethylene)-6-fluoro-1,3,4,9-tetrahydro-pyrano[3,4-b]indole, and
physiologically acceptable salts thereof. - In particular, it is preferred to use compounds selected from the group consisting of:
- 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole
- 3 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydro-pyrano[3,4-b]indole
- 4 1,1-(3-dimethylamino-3-(2-thienyl)pentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole
- 5 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole
- 6 1,1-(3-dimethylamino-3-phenylpentamethylene)-3,6-dimethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole
- 7 1,1-(3-dimethylamino-3-(4-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole
- 12 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-aza-9-oxafluorene
- 15 1,1-(3-dimethylamino-3-(3-fluorophenyl)pentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole
- 16 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-chloro-3-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole
- 18 1,1-(3-dimethylamino-3-(3-thienyl)pentamethylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole
- 21 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-1,3,4,9-tetra-hydropyrano[3,4-b]indole
- 23 1,1-(3-dimethylamino-3-phenylpentamethylene)-3-methyl-6-nitro-1,3,4,9-tetrahydropyrano[3,4-b]indole
- 24 1,1-(3-dimethylamino-3-(3-thienyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole
- 47 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-(1-benzyl-pyrazol-4-yl)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole
- 48 1,1-(3-Methylamino-3-(2-thienyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole, and
physiologically acceptable salts thereof. - It is most particularly preferred to use compounds selected from the group:
- 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole;
- 3 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole;
- 4 1,1-(3-dimethylamino-3-(2-thienyl)pentamethylene)-1,3,4,9-tetrahydro-pyrano[3,4-b]indole, and
physiologically acceptable salts thereof - Also preferred are compounds selected from the group consisting of:
- 22 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-thia-9-azafluorene;
- 27 1,1-(3-dimethylamino-3-phenylpentamethylene)-2-oxo-1,3,4,9-tetrahydro-2-thia-9-azafluorene;
- 28 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-thia-9-azafluorene;
- 34 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydro-2-thia-9-azafluorene, and
physiologically acceptable salts thereof. - The synthesis of the compounds is described in US 2006/004034 A1 and US 2005/066183 A1. The isolation of the compounds according to the invention by column chromatography with silica gel as stationary phase leads to a separation of the different polar diastereomers. These were characterised on the basis of their running time as “non-polar” diastereomer (shorter running time) and “polar” diastereomer (longer running time). Silica gel 60 (0.040-0.063 mm) from E. Merck, Darmstadt, was used. The thin-layer chromatography investigations were carried out with HPTLC precoated plates from E. Merck, Darmstadt. As solvent, for example methanol/ethyl acetate was used in a ratio of 1:1, 2:1, 3:1 or 4:1, preferably 3:1, or methanol/conc. ammonia solution 99.5:0.5 or methanol/ethyl acetate/conc. ammonia solution in a ratio of 66:33:0.5.
- The pharmaceutical compositions of the invention optionally contain, besides at least one compound according to the invention, suitable additives and/or auxiliary substances, including carrier materials, fillers, solvents, diluents, coloring agents and/or binders, and may be administered as liquid medicament forms in the form of injection solutions, drops or ointments, as semi-solid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray plasters or aerosols. The choice of the auxiliary substances etc. as well as the amounts thereof to be used depend on whether the medicament is to be administered orally, perorally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccaly, rectally or topically for example to the skin, mucus membranes or to the eyes. For oral application suitable preparations are in the form of tablets, coated tablets, capsules, granules, drops, ointments and syrups, while for parenteral, topical and inhalative application suitable forms are solutions, suspensions, readily reconstitutable dry preparations, as well as sprays. Spirocyclic cyclohexane derivatives according to the invention in depot form, in dissolved form or in a plaster form, optionally with the addition of agents promoting penetration of the skin, are suitable percutaneous application preparations. Orally or percutaneously usable preparation forms can provide for the delayed release of the compounds according to the invention. The compounds according to the invention can also be employed in parenteral long-term depot forms, such as for example implants or implanted pumps. In principle other active constituents known to the person skilled in the art can be added to the medicaments according to the invention.
- The amount of active constituent to be administered to the patient varies depending on the patient's weight, form of application, medical implications and the severity of the illness. Normally 0.00005 to 1 mg/kg, preferably 0.0001 to 0.05 mg/kg of at least one spirocyclic cyclohexane derivative according to the invention is applied.
- All the aforementioned forms of the medicaments according to the invention also may contain, in addition to at least one compound according to the invention, a further active constituent, in particular an opioid antagonist, preferably naloxone.
- For comparison purposes the standard medication levomethadone, which has no significant ORL1 component, was tested in the withdrawal jumping test. Levomethadone, which is one of the standard therapeutic agents used in substitution therapy, likewise induced withdrawal jumping. Among the compounds described in US 2006/004034 A1 and US 2005/066183 A1 are a number of substances with a slight ORL1 component. Two typical members with a slight ORL1 component (compounds m and n) were likewise tested in the withdrawal jumping test and induced withdrawal jumping. This shows the importance of the ORL1 component as regards the suitability of a substance for substitution therapy within the group of compounds described in US 2006/004034 A1 and US 2005/066183 A1.
- The properties that are desired in the standard therapeutic agents and which are to some extent manifested include:
-
- 1. High opioid potency
- 2. Full intrinsic activity
- 3. Long action duration (active metabolites such as for example in the case of LAAM are even desirable in this indication)
- 4. Slower action on set, especially with oral administration (less “kick”)
- 5. Lower cardio toxicity
Whereas with the known standard substances some of these properties are missing or are insufficiently manifested, with the compounds according to the invention all the required properties were present.
- The compounds according to the invention show significantly reduced cardiovascular side effects compared to methadone and LAAM. The cardiovascular side effects are attributed to a delayed cardiac repolarisation (manifested as a QTc extension in the outside ECG), which is caused by the blockade of a special potassium channel (HERG) (Kornick et al. Pain 2003, 105, 499-506). Both methadone and LAAM exhibit interactions with the HERG channel (Jiesheng et al., Eur. J. Pharmacol. 2003, 458, 25-29; Katchman et al., J. Pharmacol. Exp. Ther. 2002, 303, 688-694). In connection with the order issued by Orlaam (LAAM) the FDA gave a warning in 2001 about the cardiovascular effects (JAMA 2001, 285, 2705). In the case of the compounds according to the invention it was shown for example that the cardiovascular side effects are significantly less compared to methadone and LAAM.
- Within the group of spiro compounds described in US 2006/004034 A1 and US 2005/192333 A1 there are compounds with a higher and lower ORL1 component.
- The cyclohexane derivatives of the general formula I were investigated in a receptor binding assay with 3H-nociceptin/orphanin FQ with membranes of recombinant CHO-ORL1 cells. This test system was implemented according to the method proposed by Ardati et al. (Mol. Pharmacol., 51, 1997, pp. 816-824). The concentration of 3H-nociceptin/orphanin FQ in these tests was 0.5 nM. The binding assays were carried out with 20 μg of membrane protein per 200 μl of batch in 50 mM Hepes, pH 7.4, 10 mM MgCl2 and 1 mM EDTA. The binding to the ORL1 receptor was determined using in each
case 1 mg WGA-SPA beads (Amersham-Pharmacia, Freiburg), by incubating the batch for one hour at room temperature followed by measurement in a Trilux scintillation counter (Wallac, Finland). The affinity is given in Table 1 as nanomolar Kij value in or % inhibition at c=1 μM. - The receptor affinity for the human μ-opiate receptor was determined in a homogeneous batch in mikrotiter plates. For this purpose dilution series of the respective substituted cyclohexyl-1,4-diamine derivatives to be tested were incubated with a receptor membrane preparation (15-40 μg protein per 250 μl incubation batch) of CHO—K1 cells which express the human μ-opiate receptor (RB-HOM receptor membrane preparation obtained from the NEN company, Zaventem, Belgium) in the presence of 1 nmol/1 of the radioactive ligand [3H]-naloxone (NET719, NEN company, Zaventem, Belgium) as well as of 1 mg WGA-SPA beads (wheat germ agglutinin SPA Beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl for 90 minutes at room temperature. 50 mmol/l tris-HCl supplemented by 0.05 wt. % of sodium azide and 0.06 wt. % of bovine serum albumin were used as incubation buffer. In order to determine the non-specific binding, 25 μmol/l of naloxone were additionally added. After the end of the 9-minute incubation period the microtiter plates were centrifuged for 20 minutes at 1000 G and the radioactivity was measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac Company, Freiburg, Germany). The percentage displacement of the radioactive ligand from its binding to the human μ-opiate receptor at a concentration of the test substances of 1 μmol/l was determined and given as the percentage inhibition (% inhibition) of the specific binding. In some cases IC50 inhibition concentrations which effect a 50% displacement of the radioactive ligand were calculated on the basis of the percentage displacement by different concentration of the compounds of the general formula I to be tested. Ki values for the test substances were obtained by conversion using the Cheng-Prusoff relationship.
- The following table lists by way of example some compounds which, although they bind very well to the μ-opiate receptor, nevertheless have a relatively low ORL1 component:
-
ORL1/μ ratio calculated as ORL-1 μ-opiate- Ki(μ)/Ki(ORL1) [1 μM], receptor (only for measured % [1 μM], Compound Structure Ki values) inhibition % inhibition a 1 83 b 5 89 c 11 74 d 13 83 e 15 75 f 27 92 g 31 91 h 32 97 I 32 99 j 33 78 k 41 82 l 43 100 m 0.03 69 nM (Ki) 2.4 nM (Ki) n 0.1 14.3 nM (Ki) 1.8 nM (Ki) - As shown by way of example in the compounds m and n, these compounds do not suppress withdrawal jumping.
- Compared to the above, the following compounds have an almost balanced ORL1/μ ratio. Ideally, they have a more strongly pronounced ORL1 component. The ORL1:μ ratio is however at least 1:3:
-
ORL1/μ Ratio ORL1 calculated human μ as Ki(μ)/ Ki Ki No. Compound Name Remarks Ki(ORL1) [μM] [μM] 1 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-1,3,4,9- tetrahydropyrano[3,4- b]indole Hemicitrate Non-polar diastereomer 2 0.0034 0.0058 2 1,1-(3-dimethylamino- 3-benzylpentamethyl- ene)-2-(2-nitro- benzoyl)-1,3,4,9- tetrahydro-2,9- diazafluorene 0.32 0.0038 0.0012 3 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-fluoro-1,3,4,9- tetrahydropyrano[3,4- b]indole Hemicitrate Non-polar diastereomer 2.45 0.0026 0.006 4 1,1-(3-dimethylamino- 3-(2-thienyl)penta- methylene)-1,3,4,9- tetrahydropyrano[3,4- b]indole Hemicitrate Non-polar diastereomer 2.07 0.0003 0.0006 5 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-3-methyl-1,3,4,9- tetrahydropyrano[3,4- b]indole Hemicitrate Non-polar diastereomer 3.82 0.0012 0.0047 6 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-3,6-dimethyl- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Hemicitrate One of two diastereomers 3.18 0.0044 0.014 7 1,1-(3-dimethylamino- 3-(4-fluorophenyl)- pentamethylene)- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Hemicitrate One of two diastereomers 3.00 0.0032 0.010 8 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-3-hydroxymethyl- 1,3,4,9-tetrahydro-2,9- diazafluorene Dicitrate Diastereomer mixture 2.70 0.0010 0.0027 9 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-2-(2,3,4,5,6- pentafluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.32 0.13 0.041 10 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-2-(methoxy- carbonyl)-1,3,4,9- tetrahydro-2,9- diazafluorene Citrate Diastereomer Mixture 2.67 0.0009 0.0023 11 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-7-fluoro-1,3,4,9- tetrahydro-2,9- diazafluorene Citrate Polar Diastereomer 2.46 0.007 0.02 12 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-1,3,4,9- tetrahydro-2-aza-9- oxafluorene Citrate Diastereomer mixture 2.39 0.07 0.17 13 1,1-(3-dimethylamino- 3-(3-fluorophenyl)- pentamethylene)- 1,3,4,9-tetrahydro-2,9- diazafluorene Diastereomer mixture 2.22 0.0036 0.008 14 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-2-acetyl-1,3,4,9- tetrahydro-2,9- diazafluorene hydrochloride Non-polar diastereomer 1.98 0.0029 0.006 15 1,1-(3-dimethylamino- 3-(3-fluorophenyl)- pentamethylene)- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Hemicitrate One of two diastereomers 1.79 0.0012 0.0022 16 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-chloro-3- methyl-1,3,4,9- tetrahydropyrano- [3,4-b]indole Citrate Non-polar diastereomer 1.77 0.06 0.11 17 1,1-(3-dimethylamino- 3-(2-pyridyl)penta- methylene)-1,3,4,9- tetrahydro-2,9- diazafluorene Diastereomer mixture 1.75 0.0016 0.0028 18 1,1-(3-dimethylamino- 3-(3-thienyl)penta- methylene)-6-fluoro- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Hemicitrate Non-polar Diastereomer 1.62 0.0003 0.0006 19 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-2-acetyl-7-fluoro- 1,3,4,9-tetrahydro-2,9- diazafluorene Citrate Diastereomer mixture 1.41 0.0011 0.0016 20 1,1-(3-dimethylamino- 3-phenylpentamethyl- en)-1,3,4,9-tetrahydro- 2,9-diazafluorene Di- hydrochloride Diastereomer mixture 1.38 0.0003 0.0004 21 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-3-methyl-1,3,4,9- tetrahydropyrano[3,4- b]indole Citrate Diastereomer mixture 1.38 0.04 0.06 22 1,1-(3-dimethylamino- 3-phenylpentamethyl- en)-1,3,4,9-tetrahydro- 2-thia-9-azafluorene Citrate Diastereomer mixture 1.33 0.02 0.02 23 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-3-methyl-6-nitro- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Citrate Polar diastereomer 1.29 0.03 0.04 24 1,1-(3-dimethylamino- 3-(3-thienyl)penta- methylene)-1,3,4,9- tetrahydropyrano- [3,4-b]indole Hemicitrate Non-polar diastereomer 1.19 0.0006 0.0007 25 1,1-(3-dimethylamino- 3-(4-fluorophenyl)- pentamethylene)- 1,3,4,9-tetrahydro-2,9- diazafluorene Diastereomer mixture 1.12 0.0026 0.0029 26 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-3-methyl-1,3,4,9- tetrahydro-2,9- iazafluorene Citrate One of two diastereomers 0.94 0.0005 0.0005 27 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-2-oxo-1,3,4,9- tetrahydro-2-thia-9- azafluorene Citrate 0.94 0.06 0.06 28 1,1-(3-dimethylamino- 3-phenylpentamethyl- en)-1,3,4,9-tetrahydro- 2-thia-9-azafluorene Hemicitrate Non-polar diastereomer 0.84 0.0037 0.0031 29 1,1-(3-dimethylamino- 3-(2-thienyl)penta- methylene)-6-fluoro- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Hemicitrate Non-polar diastereomer 0.82 0.0007 0.0006 30 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-3-methyl-1,3,4,9- tetrahydro-2,9- diazafluorene Dihydro- chloride Diastereomer mixture 0.78 0.0006 0.0005 31 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-fluoro-3- methyl-1,3,4,9- tetrahydropyrano- [3,4-b]indole Hemicitrate One of two diastereomers 0.73 0.08 0.06 32 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-hydroxy- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Citrate One of two diastereomers 0.7 0.0016 0.0011 33 1,1-(3-dimethylamino- 3-(3-hydroxyphenyl)- pentamethylene)- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Methyl- sulfonate One of two diastereomers 0.66 0.014 0.009 34 1,1-(3-dimethylamino- 3-phenylpentamethyl- en)-1,3,4,9-tetrahydro- 2-thia-9-azafluorene Citrate Polar diastereomer 0.62 0.13 0.08 35 6,6-(3-dimethylamino- 3-phenylpentamethyl- en)-1,2,3,4,4a,6,7,11c- octahydro-5-oxa-7-aza- benzo[c]fluorine Citrate Diastereomer mixture 0.62 0.11 0.07 36 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-methyl-1,3,4,9- tetrahydropyrano- [3,4-b]indole Hemicitrate One of two diastereomers 0.60 0.0045 0.0027 37 1,1-(3-dimethylamino- 3-(4-fluorophenyl)- pentamethylene)-2- acetyl-1,3,4,9- tetrahydro-2,9- diazafluorene Citrate Diastereomer mixture 0.55 0.006 0.0033 38 1,1-(3-dimethylamino- 3-benzylpentamethyl- en)-1,3,4,9-tetrahydro- 2,9-diazafluorene One of two diastereomers 0.54 0.0011 0.0006 39 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-fluoro-1,3,4,9- tetrahydro-2,9- diazafluorene Dihydro- chloride One of two diastereomers 0.51 0.0014 0.0007 40 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-methyl-1,3,4,9- tetrahydro-2,9- diazafluorene Citrate Polar diastereomer 0.47 0.03 0.02 41 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-bromo-3- methyl-1,3,4,9- tetrahydropyrano- [3,4-b]indole Hemicitrate One of two diastereomers 0.45 0.02 0.010 42 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-fluoro-1,3,4,9- tetrahydropyrano- [3,4-b]indole Citrate Polar diastereomer 0.42 0.02 0.009 43 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-bromo-1,3,4,9- tetrahydropyrano- [3,4-b]indole Hemicitrate One of two diastereomers 0.37 0.05 0.02 44 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-methoxy- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole hydrochloride Non-polar diastereomer 0.34 0.006 0.0020 45 1,1-(3-(1-Pyrrolidyl)- 3-phenylpentamethyl- en)-1,3,4,9-tetrahydro- pyrano[3,4-b]indole Hemicitrate Non-polar diastereomer 0.31 0.0035 0.0011 46 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-7,8-dichloro- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Methane sulfonate One of two diastereomers 0.31 0.0045 0.0014 47 1,1-(3-dimethylamino- 3-phenylpentamethyl- ene)-6-(1-benzyl- pyrazol-4-yl)-1,3,4,9- tetrahydropyrano- [3,4-b]indole hydrochloride Non-polar diastereomer 2.73 0.0044 0.012 48 1,1-(3-Methylamino-3- (2-thienyl)pentameth- ylene)-1,3,4,9-tetra- hydropyrano[3,4-b]- indole One of two diastereomers 6.56 0.00032 0.0021 49 1,1-(3-Methylamino-3- (2-thienyl)pentameth- ylene)-6-fluoro- 1,3,4,9-tetrahydro- pyrano[3,4-b]indole Citrate One of two diastereomers 0.7 0.0042 0.0028 ORL1, ORL1/μ Ki μ, Ki No. Compound Name ratio [μM] [μM] 50 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-cinnamoyl-1,3,4,9- tetrahydro-2,9-diazafluorene 21.43 0.0014 0.030000 51 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3,3-dimethylbutanoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 5.00 0.0026 0.013000 52 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(cyclopentylcarbonyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 4.78 0.0067 0.032 53 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3,3- dimethylbutanoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 3.54 0.0048 0.017 54 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(pentanoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 3.42 0.0038 0.013 55 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2-furylcarbonyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 3.14 0.022 0.069 56 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- furylcarbonyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.90 0.01 0.029 57 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(4-fluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.83 0.0046 0.013 58 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2-methoxybenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.78 0.00097 0.0027 59 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- methylbutanoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.68 0.0041 0.011 60 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(cyclohexylcarbonyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 2.60 0.025 0.065 61 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-benzoyl-1,3,4,9-tetrahydro- 2,9-diazafluorene 2.50 0.0034 0.0085 62 1,1-(3-dimethylamino-3- phenylpentamethylene)-2- (cyclohexylcarbonyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.40 0.002 0.0048 63 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(phenylacetyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.35 0.002 0.0047 64 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(4-methoxybenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.29 0.038 0.087 65 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(4- trifluoromethylbenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 2.18 0.0078 0.017 66 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(thien-2-ylacetyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.12 0.017 0.036 67 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(phenylacetyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 2.07 0.0014 0.0029 68 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-butanoyl-1,3,4,9-tetrahydro- 2,9-diazafluorene 2.00 0.0014 0.0028 69 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(4- trifluoromethylbenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.91 0.011 0.021 70 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(3- fluoro-5-trifluoromethyl- benzoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 1.82 0.0077 0.014 71 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2,3-difluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.79 0.0014 0.0025 72 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(4-methylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.77 0.026 0.046 73 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- phenylpropanoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.64 0.028 0.046 74 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3,4- dichlorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.64 0.014 0.023 75 1,1-(3-dimethylamino-3- benzylpentamethylene)-2- cinnamoyl-1,3,4,9-tetrahydro- 2,9-diazafluorene 1.54 0.024 0.037 76 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(2,6- difluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.54 0.054 0.083 77 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- methoxycarbonylpropanoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.50 0.01 0.015 78 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3-chlorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.50 0.018 0.027 79 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- fluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.50 0.0028 0.0042 80 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2,6- difluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.50 0.01 0.015 81 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3,4-dichlorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.37 0.019 0.026 82 1,1-(3-dimethylamino-3- benzylpentamethylene)-2- (2,3,4,5,6-pentafluoro- benzoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 1.35 0.06 0.081 83 1,1-(3-dimethylamino-3- benzylpentamethylene)-2- cyclohexylcarbonyl-1,3,4,9- tetrahydro-2,9-diazafluorene 1.31 0.013 0.017 84 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- cyclopentylpropanoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.29 0.0093 0.012 85 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(4-fluoro-3-trifluoromethyl- benzoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 1.28 0.0071 0.0091 86 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(4-methylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.24 0.0055 0.0068 87 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3,4,5-trimethoxybenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.21 0.019 0.023 88 1,1-(3-dimethylamino-3- benzylpentamethylene)-2- cyclobutylcarbonyl-1,3,4,9- tetrahydro-2,9-diazafluorene 1.17 0.041 0.048 89 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(2,6- dichlorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.14 0.029 0.033 90 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3-methoxybenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.12 0.098 0.11 91 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- thienylcarbonyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.09 0.032 0.035 92 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-propanoyl-1,3,4,9- tetrahydro-2,9-diazafluorene 1.07 0.057 0.061 93 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2,4-difluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.06 0.016 0.017 94 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3,5-difluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.06 0.0035 0.0037 95 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(4-tert.butylbenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.06 0.0090 0.0095 96 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(3- methoxycarbonylpropanoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.05 0.066 0.069 97 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3,4-difluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.04 0.0023 0.0024 98 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- ethylhexanoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.04 0.047 0.049 99 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2-methylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.02 0.0092 0.0094 100 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- phenylpropanoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.00 0.04 0.04 101 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3-fluoro-5-trifluoro- methylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 1.00 0.0033 0.0033 102 1,1-(3-dimethylamino-3- phenyl-pentamethylene)-2-(4- fluoro-3- trifluoromethylbenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 1.00 0.036 0.036 103 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(4-nitrobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.97 0.0064 0.0062 104 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3,5- difluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.95 0.002 0.0019 105 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(2- trifluoromethylbenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.95 0.019 0.018 106 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3,4-difluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.94 0.0035 0.0033 107 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(4- chlorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.91 0.011 0.010 108 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3-methylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.91 0.011 0.010 109 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2,3,4,5-tetrafluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.90 0.002 0.0018 110 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2,6-difluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.88 0.0089 0.0078 111 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- furylcarbonyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.87 0.039 0.034 112 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2,4-dichlorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.86 0.022 0.019 113 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3-methoxycarbonyl- propanoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 0.86 0.029 0.025 114 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3-chlorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.83 0.0075 0.0062 115 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2-fluoro-5-trifluoromethyl- benzoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 0.80 0.11 0.088 116 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2-fluoro-4-trifluoro- methylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.80 0.0044 0.0035 117 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(2- thienylacetyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.79 0.014 0.011 118 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(2,6- dichlorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.78 0.093 0.073 119 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3,4- difluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.76 0.0025 0.0019 120 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(3- methylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.75 0.016 0.012 121 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- methoxycarbonylpropanoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.71 0.021 0.015 122 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2-fluoro-6-trifluoromethyl- benzoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 0.67 0.0054 0.0036 123 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- methylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.65 0.031 0.020 124 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3,5- dichlorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.64 0.0550 0.035 125 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(2- furylcarbonyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.63 0.0054 0.0034 126 1,1-(3-dimethylamino-3- benzylpentamethylene)-2- (pentanoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 0.63 0.0043 0.0027 127 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(6- fluoro-2-trifluoromethyl- benzoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 0.62 0.055 0.034 128 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3-methoxybenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.57 0.028 0.016 129 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(4- tert.butylbenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.54 0.11 0.059 130 1,1-(3-dimethylamino-3- benzylpentamethylene)-2- (phenylacetyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.54 0.0099 0.0053 131 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(3,5-dichlorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.53 0.030 0.016 132 1,1-(3-dimethylamino-3- benzylpentamethylene)-2- (2,3,4,5,6-pentafluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.52 0.075 0.039 133 1,1-(3-dimethylamino-3- benzylpentamethylene)-2-(3- nitrobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.52 0.017 0.0088 134 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- nitrobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.51 0.069 0.035 135 1,1-(3-dimethylamino-3- benzylpentamethylene)-2- (2,3,4,5-tetrafluorobenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.50 0.030 0.015 136 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- thienylacetyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.48 0.0069 0.0033 137 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- fluoro-4-trifluoromethylbenzoyl)- 1,3,4,9-tetrahydro-2,9- diazafluorene 0.48 0.065 0.031 138 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- fluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.47 0.018 0.0084 139 1,1-(3-dimethylamino-3- phenylpentamethylene)-2- (cyclobutylcarbonyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.45 0.075 0.034 140 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- methoxybenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.43 0.046 0.020 141 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2,5- difluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.42 0.0045 0.0019 142 1,1-(3-dimethylamino-3-(3- fluorophenyl)pentamethylene)- 2-(2-bromobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.41 0.046 0.019 143 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(3- fluoro-5-trifluoromethyl- benzoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 0.41 0.037 0.015 144 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2- fluoro-5-trifluoromethyl- benzoyl)-1,3,4,9-tetrahydro- 2,9-diazafluorene 0.39 0.049 0.019 145 1,1-(3-dimethylamino-3- phenylpentamethylene)-2-(2,3- difluorobenzoyl)-1,3,4,9- tetrahydro-2,9-diazafluorene 0.33 0.029 0.0096 - The test substances were applied intraperitoneally a total of seven times over two days. Five applications were made on the first day at 9:00, 10:00, 11:00, 13:00 and 15:00 hours, and on the second day at 9:00 and 11:00 hours. The first three applications were made in increasing dosages (dosage scheme), the further applications being at the dosage of the third application. The withdrawal symptoms were triggered with 30 mg/kg naloxone (i.p.) two hours after the last substance application. Immediately following this the animals were placed individually in transparent observation cages (
height 40 cm, diameter 15 cm) and the jumping reactions were counted over 15 minutes in 5-minute periods in each case. Morphine was administered in a dosage as comparison/standard. The withdrawal symptoms were quantified by counting the number of jumps over 0 to 10 minutes after application of naloxone. The number of animals per group exhibiting more than 10 jumps/10 minutes was determined and recorded as “% positive animals”. The average jumping frequency in the group was also calculated. Twelve animals were used per group. - Results of the jumping tests are shown in the accompanying Figures in which:
-
FIG. 1 is a graph of the mice jumping test results for levomethadone; -
FIG. 2 is a graph of the jumping test results for compound m; -
FIG. 3 is a graph of the jumping test results for compound n; -
FIG. 4 is a graph of the jumping test results according to Example 1; -
FIG. 5 is a graph of the jumping test results according to Example 3, and -
FIG. 6 is a graph of the jumping test results according to Example 4. - Effects of the substances on the heart rate and electrocardiograph parameters were investigated on conscious Beagle dogs. The electrocardiogram measurement was carried out as a bipolar limb lead according to Einthoven (lead II). For this purpose the Beagle dogs were placed in a special hammock-like holder (Animal sling, Havard Instruments, ZAK, Marktheidenfeld, Germany) and loosely secured. A measurement electrode was applied to each of the left and right front limbs, and a reference electrode was also applied to the rear limb. All electrodes were plate electrodes, which were fixed to the shaved skin by rubber collars. The plate electrodes were connected to a ECG pre-amplifier and the signals were continuously digitised by means of a computer-controlled data receiving and archiving system (PO-NE-MAH, Gould-Instrument Systems, USA) (digitising frequency: 2 kHz). The mean values of the following parameters were determined from 10 successive ECG intervals per measurement time: RR interval, PR interval, QRS interval and QT interval. The frequency correction of the QT interval was made according to the correction formula of Van de Water et al. (1989).
- Each of the test substances was administered as an i.v. short infusion (15 minutes) via the V. cephalica antibrachii. To quantify effects of substances, the changes in the ECG parameters over a period of 60 minutes after administration of the substance were recorded relative to the base value before administration of the substance. The statistical evaluation was carried out by means of variance analysis (ANOVA) compared to synchronous vehicle control measurements. (Van de Water A, Verheyen J, Xhonneux R, Reneman R S. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods. 1989 November; 22(3):207-17).
- Patch-Clamp, hERG Current
- Method description in: Bischoff U, Schmidt C, Netzer R, Pongs O. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol. 2000; 406(3):341-3.
- Method description in: Weeks J R, Compton L D. The cardiovascular pharmacology of prostacyclin (PGI2) in the rat. Prostaglandins 1979; 17(4):501-13.
-
TABLE A Summary of the cardiovascular effects of Example 1: Model Dose Observation Patch clamp, IC50 >> 10 μM (10 μM: 29 ± 7% hERG current inhibition) Blood pressure, Up to 14.7 μg/kg No effect heart rate, i.v.** conscious rat ECG, 10 μg/kg i.v. Significant Bradycardia (heart rate: conscious dog −40%) Non-significant extension of the QTc [van der Water] Slight (<10%) significant increase in the QRS time No effect on the PRinterval **Tail flick, rat: EC50 = 1.44 μg/kg i.v. - For comparison: the IC50 value for LAAM is 2 μm (interactions of LAAM/HERG channel, see Jiesheng et al., Eur. J. Pharmacol. 2003, 458, 25-29), the IC50 value for methadone is 9.8 μM (see Katchman et al., J. Pharmacol. Exp. Ther. 2002, 303, 688-694).
- In conscious rats, no cardiovascular effects are observed with an administration of up to 1 order of magnitude greater than the EC50 value in the tail flick test in rats of Example 1.
- The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the appended claims and equivalents thereof.
Claims (11)
1-22. (canceled)
23. A method of treating opioid dependency in a patient, said method comprising administering to said patient an effective amount of 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole in the form of a pure stereoisomer or a mixture of stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof.
24. The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole or the physiologically acceptable salt thereof is in the form of a pure enantiomer or diastereomer.
25. The method according to claim 23 , wherein the 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole or the physiologically acceptable salt thereof is in the form of a racemate.
26. The method according to claim 23 , wherein the opioid dependency is heroin, morphine or methadone dependency.
27. The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is used in combination with naloxone.
28. The method according to claim 23 , wherein the 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of its hydrochloride, citrate, methane sulfonate or hemicitrate.
29. The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is used in the form of the free base.
30. The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer.
31. The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer of the free base.
32. The method according to claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer of the free base and the opioid dependency is heroin, morphine or methadone dependency.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/310,690 US20140303125A1 (en) | 2005-04-11 | 2014-06-20 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
| US15/168,906 US20160271107A1 (en) | 2005-04-11 | 2016-05-31 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005016460A DE102005016460A1 (en) | 2005-04-11 | 2005-04-11 | Spriocyclic cyclohexane derivatives for the treatment of substance dependence |
| DE102005016460.9 | 2005-04-11 | ||
| PCT/EP2006/003176 WO2006108565A1 (en) | 2005-04-11 | 2006-04-07 | Spirocyclic cyclohexane derivatives for use in the treatment of substance dependency |
| US11/870,051 US20080221141A1 (en) | 2005-04-11 | 2007-10-10 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
| US14/310,690 US20140303125A1 (en) | 2005-04-11 | 2014-06-20 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/870,051 Continuation US20080221141A1 (en) | 2005-04-11 | 2007-10-10 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/168,906 Continuation US20160271107A1 (en) | 2005-04-11 | 2016-05-31 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20140303125A1 true US20140303125A1 (en) | 2014-10-09 |
Family
ID=36691523
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/870,051 Abandoned US20080221141A1 (en) | 2005-04-11 | 2007-10-10 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
| US12/939,274 Expired - Fee Related US8034936B2 (en) | 2005-04-11 | 2010-11-04 | Spirocyclic cyclohexane compounds useful to treat substance dependency |
| US14/310,690 Abandoned US20140303125A1 (en) | 2005-04-11 | 2014-06-20 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
| US15/168,906 Abandoned US20160271107A1 (en) | 2005-04-11 | 2016-05-31 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/870,051 Abandoned US20080221141A1 (en) | 2005-04-11 | 2007-10-10 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
| US12/939,274 Expired - Fee Related US8034936B2 (en) | 2005-04-11 | 2010-11-04 | Spirocyclic cyclohexane compounds useful to treat substance dependency |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/168,906 Abandoned US20160271107A1 (en) | 2005-04-11 | 2016-05-31 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20080221141A1 (en) |
| EP (1) | EP1868600B1 (en) |
| CY (1) | CY1113024T1 (en) |
| DE (1) | DE102005016460A1 (en) |
| DK (1) | DK1868600T3 (en) |
| ES (1) | ES2390468T3 (en) |
| PL (1) | PL1868600T3 (en) |
| PT (1) | PT1868600E (en) |
| SI (1) | SI1868600T1 (en) |
| WO (1) | WO2006108565A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018219847A1 (en) | 2017-05-29 | 2018-12-06 | Universita' Degli Studi Di Camerino | Co-activators of mop and nop receptors in the treatment of addiction to drugs and/or psychostimulants |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10252667A1 (en) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | New spiro-((cyclohexane)-tetrahydropyrano-(3,4-b)-indole) derivatives, are ORL1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain |
| DE102006019597A1 (en) * | 2006-04-27 | 2007-10-31 | Grünenthal GmbH | Spirocyclic cyclohexane derivatives |
| DE102006033114A1 (en) | 2006-07-18 | 2008-01-24 | Grünenthal GmbH | Spirocyclic azaindole derivatives |
| DE102007009235A1 (en) | 2007-02-22 | 2008-09-18 | Grünenthal GmbH | Spirocyclic cyclohexane derivatives |
| DE102007009319A1 (en) | 2007-02-22 | 2008-08-28 | Grünenthal GmbH | Spirocyclic cyclohexane derivatives |
| JP5501251B2 (en) * | 2008-01-11 | 2014-05-21 | アルバニー モレキュラー リサーチ， インコーポレイテッド | (1-Azinone) substituted pyridoindoles as MCH antagonists |
| AU2009228642B2 (en) | 2008-03-27 | 2013-11-07 | Grunenthal Gmbh | Substituted 4-aminocyclohexane derivatives |
| CN102046596B (en) | 2008-03-27 | 2013-12-25 | 格吕伦塔尔有限公司 | Substituted cyclohexane diamines |
| RU2514192C2 (en) | 2008-03-27 | 2014-04-27 | Грюненталь Гмбх | Hydroxymethyl cyclohexylamines |
| AU2009228647B2 (en) * | 2008-03-27 | 2013-07-04 | Grunenthal Gmbh | Substituted spirocyclic cyclohexane derivatives |
| JP5650637B2 (en) | 2008-03-27 | 2015-01-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | (Hetero-) aryl-cyclohexane derivatives |
| ES2375543T3 (en) | 2008-03-27 | 2012-03-01 | Grünenthal GmbH | DERIVATIVES OF ESPIRO (5.5) UNDECANO. |
| EP2448585B1 (en) * | 2009-07-01 | 2014-01-01 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
| WO2011003007A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| WO2011003012A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| WO2011003021A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| TWI582092B (en) * | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine derivatives |
| US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
| CN106939005A (en) * | 2011-07-08 | 2017-07-11 | 格吕伦塔尔有限公司 | Crystalline state（1r,4r）The H spiral shells of 6 ' 4 ', 9 ' dihydro of fluorine N, N 4 phenyl of dimethyl 3 ' [pyrans of hexamethylene 1,1 ' simultaneously [3,4, b] indoles] 4 amine |
| US8614245B2 (en) | 2011-07-08 | 2013-12-24 | Gruenenthal Gmbh | Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine |
| EP2970284B1 (en) * | 2013-03-15 | 2017-11-01 | Grünenthal GmbH | Crystalline cis-(e)-4-(3-fluorophenyl)-2',3',4',9'-tetrahydro-n,n-dimethyl-2'-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1'[1h]-pyrido[3,4-b]indol]-4-amine |
| US10214520B2 (en) | 2014-07-15 | 2019-02-26 | Gruenenthal Gmbh | Substituted azaspiro(4.5)decane derivatives |
| TW201607923A (en) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | Substituted azaspiro (4.5) decane derivatives |
| EP3247352B1 (en) | 2015-01-23 | 2020-06-24 | Grünenthal GmbH | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288560B2 (en) * | 2003-12-23 | 2007-10-30 | Gruenenthal Gmbh | Spirocyclic cyclohexane derivatives |
| US7951948B2 (en) * | 2002-11-11 | 2011-05-31 | Gruenenthal Gmbh | Spirocyclic cyclohexane compounds |
| US8124788B2 (en) * | 2006-04-27 | 2012-02-28 | Gruenenthal Gmbh | Spirocyclic cyclohexane compounds with analgesic activity |
| US8399503B2 (en) * | 2006-07-18 | 2013-03-19 | Gruenenthal Gmbh | Spirocyclic azaindole derivatives |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1055203A (en) * | 1964-09-16 | 1967-01-18 | Ici Ltd | -ß-carboline derivatives, a process for their manufacture, and compositions containing them |
| US4291039A (en) * | 1980-08-08 | 1981-09-22 | Miles Laboratories, Inc. | Tetrahydro β-carbolines having anti-hypertensive activity |
| DE3309596A1 (en) * | 1982-08-05 | 1984-04-05 | Basf Ag, 6700 Ludwigshafen | 2-SUBSTITUTED 1- (3'-AMINOALKYL) -1,2,3,4-TETRAHYDRO-SS-CARBOLINE, THEIR PRODUCTION AND USE AS MEDICINAL PRODUCT |
| US5328905A (en) * | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| US5369691A (en) * | 1993-03-04 | 1994-11-29 | Utilex, Inc. | Telephonic information communication method and apparatus |
| EP0620222A3 (en) * | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
| US5631265A (en) * | 1994-03-11 | 1997-05-20 | Eli Lilly And Company | 8-substituted tetrahydro-beta-carbolines |
| TWI317360B (en) * | 2001-11-07 | 2009-11-21 | Schering Corp | Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| EP1633751A1 (en) * | 2003-06-16 | 2006-03-15 | Chroma Therapeutics Limited | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
| DE10360792A1 (en) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclic cyclohexane derivatives |
| CA2588389A1 (en) * | 2004-11-23 | 2006-06-22 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting vegf production |
| US20060192333A1 (en) * | 2005-02-25 | 2006-08-31 | Aaron Dejuan Young, Trustee Of The Kenneth Brian Young Trust | Method and apparatus for playing a board and computer game |
| EP1747779A1 (en) * | 2005-07-28 | 2007-01-31 | Laboratorios Del Dr. Esteve, S.A. | Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands |
| US20070149557A1 (en) * | 2005-11-21 | 2007-06-28 | Amgen Inc. | CXCR3 antagonists |
-
2005
- 2005-04-11 DE DE102005016460A patent/DE102005016460A1/en not_active Ceased
-
2006
- 2006-04-07 EP EP06724117A patent/EP1868600B1/en not_active Not-in-force
- 2006-04-07 WO PCT/EP2006/003176 patent/WO2006108565A1/en not_active Ceased
- 2006-04-07 SI SI200631368T patent/SI1868600T1/en unknown
- 2006-04-07 ES ES06724117T patent/ES2390468T3/en active Active
- 2006-04-07 PT PT06724117T patent/PT1868600E/en unknown
- 2006-04-07 PL PL06724117T patent/PL1868600T3/en unknown
- 2006-04-07 DK DK06724117.4T patent/DK1868600T3/en active
-
2007
- 2007-10-10 US US11/870,051 patent/US20080221141A1/en not_active Abandoned
-
2010
- 2010-11-04 US US12/939,274 patent/US8034936B2/en not_active Expired - Fee Related
-
2012
- 2012-08-13 CY CY20121100720T patent/CY1113024T1/en unknown
-
2014
- 2014-06-20 US US14/310,690 patent/US20140303125A1/en not_active Abandoned
-
2016
- 2016-05-31 US US15/168,906 patent/US20160271107A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951948B2 (en) * | 2002-11-11 | 2011-05-31 | Gruenenthal Gmbh | Spirocyclic cyclohexane compounds |
| US7288560B2 (en) * | 2003-12-23 | 2007-10-30 | Gruenenthal Gmbh | Spirocyclic cyclohexane derivatives |
| US8124788B2 (en) * | 2006-04-27 | 2012-02-28 | Gruenenthal Gmbh | Spirocyclic cyclohexane compounds with analgesic activity |
| US8399503B2 (en) * | 2006-07-18 | 2013-03-19 | Gruenenthal Gmbh | Spirocyclic azaindole derivatives |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018219847A1 (en) | 2017-05-29 | 2018-12-06 | Universita' Degli Studi Di Camerino | Co-activators of mop and nop receptors in the treatment of addiction to drugs and/or psychostimulants |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006108565A1 (en) | 2006-10-19 |
| US20160271107A1 (en) | 2016-09-22 |
| PT1868600E (en) | 2012-08-28 |
| SI1868600T1 (en) | 2012-08-31 |
| US8034936B2 (en) | 2011-10-11 |
| US20080221141A1 (en) | 2008-09-11 |
| CY1113024T1 (en) | 2016-04-13 |
| DE102005016460A1 (en) | 2006-10-19 |
| US20110053970A1 (en) | 2011-03-03 |
| EP1868600A1 (en) | 2007-12-26 |
| EP1868600B1 (en) | 2012-06-27 |
| DK1868600T3 (en) | 2012-08-27 |
| PL1868600T3 (en) | 2012-11-30 |
| ES2390468T3 (en) | 2012-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8034936B2 (en) | Spirocyclic cyclohexane compounds useful to treat substance dependency | |
| US11241429B2 (en) | Method of treating metabolic disorders and depression with dopamine receptor agonists | |
| US20150342929A1 (en) | Mixed ORL1/mu-agonists for the Treatment of Pain | |
| US9119848B2 (en) | Morphinan derivatives for the treatment of drug overdose | |
| Allen et al. | Opiate pharmacology of intrathecal granulomas. | |
| France et al. | Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine. | |
| Dortch‐Carnes et al. | Bremazocine: A κ‐Opioid Agonist with Potent Analgesic and Other Pharmacologic Properties | |
| US6476044B1 (en) | Use of morphine derivatives as medicaments for the treatment of neuropathic problems | |
| EP2014288A1 (en) | Combination of benzyl-4, 5-dihydro-1H-imidazole derivative and an opioid receptor ligand | |
| AU2006268680B2 (en) | Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) | |
| JPWO2009001764A1 (en) | Treatment or prevention of schizophrenia | |
| US20060199866A1 (en) | Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse | |
| EP1870096A2 (en) | Compositions for affecting weight loss | |
| US20090281194A1 (en) | Combinations for treating HIV-associated pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |